Solid forms of substituted pyrazolopyrimidines and uses thereof

JP2023548148A5Inactive Publication Date: 2024-11-07KSQ THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526247
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-28
Publication Date
2024-11-07
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing substituted pyrazolopyrimidines as USP1 inhibitors lack optimal properties for therapeutic use, such as high affinity, duration of USP1 inactivation, oral bioavailability, solubility, and stability, which are crucial for effective pharmaceutical formulations.

Method used

Development of solid forms of substituted pyrazolopyrimidines, including crystalline and amorphous forms, and their pharmaceutically acceptable salts, solvates, and co-crystals, characterized by specific XRPD patterns and thermal stability, to enhance properties like solubility, stability, and manufacturability.

Benefits of technology

The solid forms of substituted pyrazolopyrimidines improve therapeutic efficacy by providing enhanced stability, solubility, and manufacturability, leading to improved pharmaceutical formulations for cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022094096000001
    Figure 2022094096000001
  • Figure 2022094096000002
    Figure 2022094096000002
  • Figure 2022094096000003
    Figure 2022094096000003
Patent Text Reader

Abstract

The present disclosure relates to a) solid forms of the compound of formula (I), the compound of formula (II), and the compound of formula (III); b) pharmaceutical compositions comprising one or more solid forms of the compound of formula (I), the compound of formula (II), and the compound of formula (III), and optionally a pharmaceutically acceptable carrier or diluent; c) methods of treating tumors or cancer by administering one or more solid forms of the compound of formula (I), the compound of formula (II), and the compound of formula (III) to a subject in need thereof; and d) methods of preparing the solid forms of the compound of formula (I), the compound of formula (II), and the compound of formula (III). JPEG2023548148000075.jpg129164
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority over U.S. Provisional Patent Application No. 63 / 107,765, filed on 30 October 2020, which is incorporated herein by reference in its entirety.

[0002] This disclosure relates to a solid form of a substituted pyrazolopyrimidine, a pharmaceutical composition thereof, a method for treating cancer by administering one or more solid forms of a substituted pyrazolopyrimidine, and a method for preparing a solid form of a substituted pyrazolopyrimidine. [Background technology]

[0003] Substituted pyrazolopyrimidines such as 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) are inhibitors of ubiquitin-specific processing protease 1 (USP1).

[0004] Not all USP1 inhibitor compounds possess the properties that maximize their potential as useful therapeutic agents. Some of these properties include high affinity for USP1, duration of USP1 inactivation, oral bioavailability, solubility, and stability (e.g., formulation ability, crystallization ability, or shelf life). Favorable properties can lead to improvements in stability, tolerability, efficacy, therapeutic index, patient adherence, cost-effectiveness, and ease of manufacture.

[0005] In addition, formula (II) 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and formula (III) 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-py There are many challenges in isolating and commercially preparing corresponding pharmaceutical formulations of substituted pyrazolopyrimidines such as lazolo[3,4-d]pyrimidines with solid form and acceptable solid form characteristics (including chemical stability, thermal stability, solubility, hygroscopicity, and / or particle size), as well as in the manufacturability of the compounds (including yield, impurity removal during crystallization, filtration properties, drying properties, and grinding properties), and the feasibility of the formulations (including stability against pressure or compressive force during tableting).

[0006] Therefore, there is currently a need for one or more solid forms of substituted pyrazolopyrimidines, such as 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazolo-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), that possess these properties in an acceptable balance and can be used in the preparation of pharmaceutically acceptable solid dosage forms. [Overview of the Initiative] [Means for solving the problem]

[0007] In one embodiment, the present disclosure relates to the solid form of a compound of formula (I), [ka] or with respect to a pharmaceutically acceptable salt thereof, During the ceremony,

[0008] R is C alkyl,

[0009] X1 and X2 are independently selected from the group consisting of N and C.

[0010] In some embodiments, the solid form is a solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II),

Chemical formula

[0011] In some embodiments, the solid form is a crystalline form of the compound of formula (II). In some embodiments, the crystalline form is a hydrate, an anhydrate, or a solvate thereof. In some embodiments, the solvate is a dichloromethane solvate.

[0012] In some embodiments, the solid form is an amorphous form of the compound of formula (II). In some embodiments, the amorphous form is a hydrate, an anhydrate, or a solvate thereof.

[0013] In some embodiments, the solid form of the compound of formula (II) is a) Crystalline form A, characterized by an XRPD pattern having peaks at 14.3 ± 0.2°, 21.5 ± 0.2°, and 21.8 ± 0.2° 2θ; b) Crystalline form C, characterized by an XRPD pattern having peaks at 14.2 ± 0.2°, 17.0 ± 0.2°, and 19.1 ± 0.2° 2θ; c) Crystalline form D, characterized by an XRPD pattern having peaks at 13.9 ± 0.2°, 15.2 ± 0.2°, and 19.3 ± 0.2° 2θ; d) Crystal morphology E characterized by an XRPD pattern having peaks at 10.6±0.2°, 18.7±0.2°, and 20.9±0.2°²θ; and, e) Crystal morphology F, characterized by an XRPD pattern having peaks at 10.7±0.2°, 14.3±0.2°, and 21.8±0.2°²θ, It is selected from the group consisting of the following.

[0014] In some embodiments, the solid form of the compound of formula (II) is a) Crystal morphology A, characterized by an XRPD pattern having peaks at 14.3±0.2°, 21.5±0.2°, and 21.8±0.2°²θ; b) Crystal morphology C characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, and 19.1±0.2°²θ; c) Crystal morphology D, characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, and 19.3±0.2°²θ; and d) Crystal morphology E characterized by an XRPD pattern having peaks at 10.6±0.2°, 18.7±0.2°, and 20.9±0.2°²θ, It is selected from the group consisting of the following.

[0015] In some embodiments, the solid form of the compound of formula (II) is crystalline form A. In some embodiments, crystalline form A is characterized by an XRPD pattern as shown in Figure 1. In some embodiments, crystalline form A is characterized by an endothermic peak at approximately 165°C when measured by DSC. In some embodiments, crystalline form A is characterized by a DSC profile as shown in Figure 2. In some embodiments, crystalline form A is characterized by a decrease of approximately 0.93 wt% between room temperature and approximately 150°C when measured by TGA. In some embodiments, crystalline form A is characterized by a TGA profile as shown in Figure 2.

[0016] In some embodiments, the crystal morphology A is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 1, b) a DSC profile as shown in Figure 2, or c) a TGA profile as shown in Figure 2.

[0017] In some embodiments, crystalline form A substantially does not contain other polymorphic forms. In some embodiments, crystalline form A has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0018] In some embodiments, crystalline form A has a unit cell classified as monoclinic. In some embodiments, crystalline form A has a unit cell with an a value of approximately 12.054 Å, a b value of approximately 8.775 Å, and a c value of approximately 24.837 Å. In some embodiments, crystalline form A has a volume of approximately 2603.68 Å. 3 It has a unit cell.

[0019] In other embodiments, the disclosure relates to mixtures comprising crystalline form A and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to mixtures comprising crystalline form A in proportion to other solid forms of the compound of formula (II). The compositions of the solid-form mixtures disclosed herein can be determined using methods known in the art (see, for example, Varasteh, M., et al., Int. J. Pharm. 366(1-2):74-81 (2009)).

[0020] In some embodiments, the solid form of the compound of formula (II) is crystalline form C. In some embodiments, crystalline form C is characterized by an XRPD pattern as shown in Figure 3.

[0021] In some embodiments, crystalline form C is substantially free of other polymorphic forms. In some embodiments, crystalline form C has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0022] In another embodiment, the disclosure relates to a mixture comprising crystalline form C and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form C in proportion to other solid forms of the compound of formula (II).

[0023] In some embodiments, the solid form of the compound of formula (II) is crystalline form D. In some embodiments, crystalline form D is characterized by an XRPD pattern as shown in Figure 4.

[0024] In some embodiments, crystalline form D substantially does not contain other polymorphic forms. In some embodiments, crystalline form D has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0025] In another embodiment, the disclosure relates to a mixture comprising crystalline form D and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form D in proportion to other solid forms of the compound of formula (II).

[0026] In some embodiments, the solid form of the compound of formula (II) is crystalline form E. In some embodiments, crystalline form E is characterized by an XRPD pattern as shown in Figure 5. In some embodiments, crystalline form E is characterized by an endothermic peak at approximately 107°C when measured by DSC. In some embodiments, crystalline form E is characterized by a DSC profile as shown in Figure 6. In some embodiments, crystalline form E is characterized by a decrease of approximately 13.5 wt% between room temperature and approximately 200°C when measured by TGA. In some embodiments, crystalline form E is characterized by a TGA profile as shown in Figure 6.

[0027] In some embodiments, the crystalline morphology E is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 5, b) a DSC profile as shown in Figure 6, or c) a TGA profile as shown in Figure 6.

[0028] In some embodiments, crystalline form E substantially does not contain other polymorphic forms. In some embodiments, crystalline form E has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0029] In another embodiment, the disclosure relates to a mixture comprising crystalline form E and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form E in proportion to other solid forms of the compound of formula (II).

[0030] In some embodiments, the solid form of the compound of formula II is crystalline form F. In some embodiments, crystalline form F is characterized by an XRPD pattern as shown in Figure 25. In some embodiments, crystalline form F is characterized by an endothermic peak at approximately 157°C when measured by DSC. In some embodiments, crystalline form F is characterized by a DSC profile as shown in Figure 26.

[0031] In some embodiments, the crystalline morphology F is characterized by at least one of the following: a) an XRPD pattern as shown in Figure 25, or b) a DSC profile as shown in Figure 26.

[0032] In some embodiments, the crystalline form F is substantially free of other polymorphic forms. In some embodiments, the crystalline form F has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0033] In another embodiment, the disclosure relates to a mixture comprising crystalline form F and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form F for the majority of the mixture compared to other solid forms of the compound of formula (II).

[0034] In some embodiments, the solid form of the compound of formula (II) is a pharmaceutically acceptable salt of the compound of formula (II).

[0035] In some embodiments, a pharmaceutically acceptable salt is formed between the compound of formula (II) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, The acid is selected from the group consisting of tansulfonic acid, mucoic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, the benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with two hydroxyl groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with three hydroxyl groups is gallic acid.In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.

[0036] In some embodiments, the solid form of the compound of formula (II) is the crystalline form of a pharmaceutically acceptable salt of the compound of formula (II). In some embodiments, the crystalline form of the pharmaceutically acceptable salt is a hydrate, an anhydride, or a solvate thereof.

[0037] In some embodiments, the solid form of the compound of formula (II) is the amorphous form of a pharmaceutically acceptable salt of the compound of formula (II). In some embodiments, the amorphous form of the pharmaceutically acceptable salt is a hydrate, an anhydrous, or a solvate thereof.

[0038] In some embodiments, the pharmaceutically acceptable salt of the compound of formula (II) is a hydrochloride. In some embodiments, the hydrochloride is crystalline morphology 1 characterized by an XRPD pattern having peaks at 12.5±0.2°, 22.4±0.2°, and 23.9±0.2°²θ. In some embodiments, the hydrochloride is characterized by an XRPD pattern as shown in Figure 7. In some embodiments, the hydrochloride is characterized by an endothermic peak at approximately 142.1°C when measured by DSC. In some embodiments, the hydrochloride is characterized by a DSC profile as shown in Figure 8. In some embodiments, the hydrochloride is characterized by a decrease of approximately 4.04 wt% between approximately 30°C and approximately 100°C when measured by TGA. In some embodiments, the hydrochloride is characterized by a TGA profile as shown in Figure 8.

[0039] In some embodiments, the crystal morphology 1 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 7, b) a DSC profile as shown in Figure 8, or c) a TGA profile as shown in Figure 8.

[0040] In some embodiments, crystalline form 1 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0041] In another embodiment, the disclosure relates to a mixture comprising crystalline form 1 and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form 1 in proportion to other solid forms of the compound of formula (II).

[0042] In some embodiments, the solid form of the compound of formula (II) is a pharmaceutically acceptable cocrystal of the compound of formula (II) and a second pharmaceutically acceptable compound.

[0043] In some embodiments, a pharmaceutically acceptable cocrystal is formed between the compound of formula (II) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, The acid is selected from the group consisting of tansulfonic acid, mucoic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, the benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with two hydroxyl groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups.In some embodiments, the benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.

[0044] In some embodiments, the pharmaceutically acceptable cocrystal of the compound of formula (II) is gentisinate cocrystal. In some embodiments, the gentisinate cocrystal is crystalline morphology 2 characterized by an XRPD pattern having peaks at 16.6±0.2°, 18.7±0.2°, and 22.5±0.2°²θ. In some embodiments, the gentisinate cocrystal is characterized by an XRPD pattern as shown in Figure 9. In some embodiments, the gentisinate cocrystal is characterized by an endothermic peak at approximately 186.0°C when measured by DSC. In some embodiments, the gentisinate cocrystal is characterized by a DSC profile as shown in Figure 10. In some embodiments, the gentisinate cocrystal is characterized by a decrease of approximately 3.17 wt% between room temperature and approximately 170°C when measured by TGA. In some embodiments, the gentisinate cocrystal is characterized by a TGA profile as shown in Figure 10.

[0045] In some embodiments, the crystal morphology 2 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 9, b) a DSC profile as shown in Figure 10, or c) a TGA profile as shown in Figure 10.

[0046] In some embodiments, crystalline form 2 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 2 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0047] In some embodiments, crystal morphology 2 has a unit cell classified as monoclinic. In some embodiments, crystal morphology 2 has a unit cell with an a value of approximately 11.113 Å, a b value of approximately 12.356 Å, and a c value of approximately 24.048 Å. In some embodiments, crystal morphology 2 has a volume of approximately 3223.93 Å. 3 It has a unit cell.

[0048] In another embodiment, the disclosure relates to a mixture comprising crystalline form 2 and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form 2 in proportion to other solid forms of the compound of formula (II).

[0049] In some embodiments, the pharmaceutically acceptable cocrystal of the compound of formula (II) is a benzoic acid cocrystal. In some embodiments, the benzoic acid cocrystal is a crystalline morphology characterized by an XRPD pattern having peaks at 12.1±0.2°, 14.2±0.2°, and 16.5±0.2°²θ. In some embodiments, the benzoic acid cocrystal is characterized by an XRPD pattern as shown in Figure 29. In some embodiments, the benzoic acid cocrystal is characterized by an endothermic peak at approximately 105°C when measured by DSC. In some embodiments, the benzoic acid cocrystal is characterized by a DSC profile as shown in Figure 30.

[0050] In some embodiments, the benzoic acid cocrystal is characterized by a decrease of approximately 18.8% by weight between approximately 120°C and approximately 300°C. In some embodiments, the benzoic acid cocrystal is characterized by a TG-FTIR profile as shown in Figure 31.

[0051] In some embodiments, the crystal morphology 8 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 29, b) a DSC profile as shown in Figure 30, or c) a TG-FTIR profile as shown in Figure 31.

[0052] In some embodiments, crystalline form 8 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 8 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0053] In some embodiments, crystal morphology 8 has a unit cell classified as monoclinic. In some embodiments, crystal morphology 8 has a unit cell with an a value of approximately 10.61070(10) Å, a b value of approximately 12.39940(10) Å, and a c value of approximately 24.15170(10) Å. In some embodiments, crystal morphology 8 has a volume of approximately 3114.74(4) Å 3 It has a unit cell.

[0054] In another embodiment, the disclosure relates to a mixture comprising crystalline form 8 and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form 8 in proportion to other solid forms of the compound of formula (II).

[0055] In some embodiments, the pharmaceutically acceptable cocrystal of the compound of formula (II) is a salicylic acid cocrystal. In some embodiments, the salicylic acid cocrystal is a crystalline morphology 9 characterized by an XRPD pattern having peaks at 11.0±0.2°, 16.5±0.2°, 17.3±0.2° and 25.3±0.2°²θ. In some embodiments, the salicylic acid cocrystal is characterized by an XRPD pattern as shown in Figure 33. In some embodiments, the salicylic acid cocrystal is as shown in Figure 34. 1 Characterized by 1H NMR spectra.

[0056] In some embodiments, the crystal morphology 9 is a) an XRPD pattern as shown in Figure 33, or b) as shown in Figure 34. 1 Characterized by at least one of the 1H NMR profiles.

[0057] In some embodiments, crystalline form 9 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 9 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0058] In some embodiments, crystal morphology 9 has a unit cell classified as monoclinic. In some embodiments, crystal morphology 9 has a unit cell with an a value of approximately 10.8387(11) Å, a b value of approximately 12.3761(12) Å, and a c value of approximately 24.242(2) Å. In some embodiments, crystal morphology 9 has a volume of approximately 3173.1(5) Å. 3 It has a unit cell.

[0059] In another embodiment, the disclosure relates to a mixture comprising crystalline form 9 and a second solid form of the compound of formula (II). In some embodiments, the disclosure relates to a mixture comprising crystalline form 9 in proportion to other solid forms of the compound of formula (II).

[0060] In some embodiments, the solid form is the solid form of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), [ka] or a pharmaceutically acceptable salt thereof.

[0061] In some embodiments, the solid form is the crystalline form of the compound of formula (III). In some embodiments, the crystalline form is the hydrate, anhydrous, or solvate thereof.

[0062] In some embodiments, the solid form is the amorphous form of the compound of formula (III). In some embodiments, the amorphous form is the hydrate, anhydrous, or solvate thereof.

[0063] In some embodiments, the solid form of the compound of formula (III) is a) Crystal morphology A1 characterized by an XRPD pattern having peaks at 16.1±0.2°, 16.7±0.2°, and 24.8±0.2°²θ; b) Selected from the group consisting of crystal morphology B1 characterized by an XRPD pattern having peaks at 12.9±0.2°, 14.5±0.2°, and 22.6±0.2°²θ.

[0064] In some embodiments, the solid form of the compound of formula (III) is crystalline form A1. In some embodiments, crystalline form A1 is characterized by an XRPD pattern as shown in Figure 11. In some embodiments, crystalline form A1 is characterized by an endothermic peak at approximately 150.5°C when measured by DSC. In some embodiments, crystalline form A1 is characterized by a DSC profile as shown in Figure 12. In some embodiments, crystalline form A1 is characterized by a decrease of approximately 0.95 wt% between room temperature and approximately 120°C when measured by TGA. In some embodiments, crystalline form A1 is characterized by a TGA profile as shown in Figure 12.

[0065] In some embodiments, the crystal morphology A1 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 11, b) a DSC profile as shown in Figure 12, or c) a TGA profile as shown in Figure 12.

[0066] In some embodiments, crystalline form A1 is substantially free of other polymorphic forms. In some embodiments, crystalline form A1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0067] In some embodiments, crystalline form A1 has a unit cell classified as monoclinic. In some embodiments, crystalline form A1 has a unit cell with an a value of approximately 12.545 Å, a b value of approximately 8.640 Å, and a c value of approximately 21.660 Å. In some embodiments, crystalline form A1 has a volume of approximately 2336.13 Å. 3 It has a unit cell.

[0068] In another embodiment, the disclosure relates to a mixture comprising crystalline form A1 and a second solid form of the compound of formula (III). In some embodiments, the disclosure relates to a mixture comprising mostly crystalline form A1 compared to other solid forms of the compound of formula (III).

[0069] In some embodiments, the solid form of the compound of formula (III) is crystalline form B1. In some embodiments, crystalline form B1 is characterized by an XRPD pattern as shown in Figure 13. In some embodiments, crystalline form B1 is characterized by an endothermic peak at approximately 161.2°C when measured by DSC. In some embodiments, crystalline form B1 is characterized by a DSC profile as shown in Figure 14. In some embodiments, crystalline form B1 is characterized by a decrease of approximately 1.58 wt% between room temperature and approximately 120°C when measured by TGA. In some embodiments, crystalline form B1 is characterized by a TGA profile as shown in Figure 14.

[0070] In some embodiments, the crystal morphology B1 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 13, b) a DSC profile as shown in Figure 14, or c) a TGA profile as shown in Figure 14.

[0071] In some embodiments, crystalline form B1 substantially does not contain other polymorphic forms. In some embodiments, crystalline form B1 has a polymorphic purity of at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0072] In another embodiment, the disclosure relates to a mixture comprising crystalline form B1 and a second solid form of the compound of formula (III). In some embodiments, the disclosure relates to a mixture comprising crystalline form B1 in proportion to other solid forms of the compound of formula (III).

[0073] In some embodiments, the solid form of the compound of formula (III) is a pharmaceutically acceptable salt or cocrystal of the compound of formula (III).

[0074] In some embodiments, a pharmaceutically acceptable salt or cocrystal is formed between the compound of formula (III) and a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable acid is 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, The acid is selected from the group consisting of tansulfonic acid, mucoic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, the benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with two hydroxyl groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups.In some embodiments, the benzoic acid derivative substituted with three hydroxyl groups is gallic acid. In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.

[0075] In one embodiment, the present disclosure relates to a pharmaceutical composition comprising one or more of the solid forms or mixtures described above, and one or more pharmaceutically acceptable carriers or diluents.

[0076] In another aspect, the present disclosure relates to a solid dosage form comprising one or more of the solid forms or mixtures described above.

[0077] In another aspect, the disclosure relates to a method for treating cancer, comprising administering one or more of the solid forms, mixtures, pharmaceutical compositions, or solid dosage forms described above to a patient in need.

[0078] In another aspect, the disclosure relates to the use of one or more of the above-described solid forms, mixtures, pharmaceutical compositions, or solid dosage forms for the manufacture of a drug for the treatment of cancer.

[0079] In another aspect, the disclosure relates to one or more of the above-described solid forms, mixtures, pharmaceutical compositions, or solid dosage forms for use in methods of treating cancer.

[0080] In another aspect, the present disclosure relates to a method for preparing crystalline form 2 of a gentisic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), [ka] The method is, a) Dissolve a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid in a suitable amount of a suitable solvent at room temperature to prepare a solution, b) Add a suitable amount of a suitable poor solvent, c) Add a seed crystal of crystalline form 2 of the gentisic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), d) Stirring the resulting suspension, e) Collecting the solid product generated in step d), and the following:

[0081] In some embodiments, a method for preparing crystalline form 2 of a gentisic acid cocrystal of the compound of formula (II) further includes adding a suitable poor solvent after step c) and before step d).

[0082] In some embodiments, a preferred solvent is ethyl acetate.

[0083] In some embodiments, a suitable poor solvent is n-heptane.

[0084] In another aspect, the present disclosure relates to a method for preparing crystalline form 2 of a gentisic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), wherein the method is a) Adding a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid to a suitable solvent system at room temperature to obtain a suspension, b) Stirring the suspension from step a), c) Collecting the solid product generated in step b).

[0085] In some embodiments, preferred solvent systems are selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.

[0086] In another aspect, the present disclosure relates to crystalline form 2 of a gentisic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods described above. [Brief explanation of the drawing]

[0087] [Figure 1] This is the powder X-ray diffraction pattern ("XRPD") corresponding to crystal morphology A. [Figure 2] These are differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) temperature records corresponding to crystal morphology A. [Figure 3] This is the XRPD pattern corresponding to crystal morphology C. [Figure 4] This is the XRPD pattern corresponding to crystal morphology D. [Figure 5] This is the XRPD pattern corresponding to crystal morphology E. [Figure 6] These are DSC and TGA temperature records corresponding to crystal morphology E. [Figure 7] This is the XRPD pattern corresponding to crystal morphology 1. [Figure 8]These are DSC and TGA temperature records corresponding to crystal morphology 1. [Figure 9] This is the XRPD pattern corresponding to crystal morphology 2. [Figure 10] These are DSC and TGA temperature records corresponding to crystal morphology 2. [Figure 11] This is the XRPD pattern corresponding to crystal morphology A1. [Figure 12] These are DSC and TGA temperature records corresponding to crystal morphology A1. [Figure 13] This is the XRPD pattern corresponding to crystal morphology B1. [Figure 14] These are DSC and TGA temperature records corresponding to crystal morphology B1. [Figure 15] This is the XRPD pattern corresponding to crystal morphology 3. [Figure 16] This is the XRPD pattern corresponding to crystal morphology 4. [Figure 17] This is the XRPD pattern corresponding to crystal morphology 5. [Figure 18] This is the XRPD pattern corresponding to crystal morphology 6. [Figure 19] This is the XRPD pattern corresponding to crystal morphology 7. [Figure 20] It is the asymmetric unit of crystalline form A in a single crystal structure. [Figure 21] It is an asymmetric unit of crystal morphology 2 in a single crystal structure. [Figure 22] It is the asymmetric unit of crystal morphology A1 in a single crystal structure. [Figure 23] This shows the time course of plasma concentration after administering crystalline form A to NOD / SCID mice at a dose of 300 mg / kg. [Figure 24] This shows the time course of plasma concentration after administering crystalline form 2 to NOD / SCID mice at a dose of 300 mg / kg. [Figure 25] This is the XRPD pattern corresponding to crystal morphology F. [Figure 26] This is a DSC temperature record corresponding to crystal morphology F. [Figure 27] This is the XRPD pattern corresponding to crystal morphology C. [Figure 28] This is the Raman spectrum corresponding to crystal morphology C. [Figure 29] This is the XRPD pattern corresponding to crystal morphology 8. [Figure 30] This is a DSC temperature record corresponding to crystal morphology 8. [Figure 31] This is a TG-FTIR temperature record corresponding to crystal morphology 8. [Figure 32] It is an asymmetrical unit of crystal morphology 8 in a single crystal structure. [Figure 33] This is the XRPD pattern corresponding to crystal morphology 9. [Figure 34] This is the 1H NMR spectrum corresponding to crystal morphology 9. [Figure 35] It is an asymmetrical unit of crystal morphology 9 in a single crystal structure. [Figure 36] This shows the time course of plasma concentration after administering 300 mg / kg of crystalline form 8 to NOD / SCID mice. [Figure 37] This shows the time course of brain and plasma concentrations after repeated oral administration of crystalline form 2 at 100 mg / kg and 300 mg / kg once daily to NOD / SCID female mice. [Figure 38] This shows the time course of brain and plasma concentrations after oral administration of crystalline form 2 at 100 mg / kg to male and female SD rats. [Modes for carrying out the invention]

[0088] I. Definition To facilitate understanding of the disclosures contained herein, several terms are defined below.

[0089] In general, the terminology used herein, as well as the clinical laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein, are well known and commonly used in the art. Unless otherwise defined, all technical and scientific terms used herein have generally the same meaning as those commonly understood by those skilled in the art to whom this disclosure relates.

[0090] The XRPD, DSC, and TGA characterization data referred to throughout this application and the claims were measured using the instruments and conditions specified at the beginning of the Examples section, under the subheading "Instrument Conditions".

[0091] In this specification and the appended claims, the singular forms "a", "an", and "the" include the plural referents unless the context clearly dictates otherwise. The terms "a" (or "an"), as well as the terms "one or more" and "at least one", may be used interchangeably herein. In certain embodiments, the term "a" or "an" means "single". In other embodiments, the terms "a" or "an" include "two or more" or "plural".

[0092] Furthermore, "and / or" as used herein should be construed as the disjunction of each of the two specified features or components, regardless of the presence or absence of the other. Thus, the term "and / or" as used in phrases such as "A and / or B" herein is intended to include "A and B", "A or B", "A" (alone), and "B" (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to include the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0093] The term "compound of formula (I)" refers to a compound included within the scope of the following structure,

Chemical formula

[0094] In some embodiments, R can be selected from methyl, ethyl, n-propyl, isopropyl, and cyclopropyl.

[0095] The term "compound of formula (II)" refers to 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, which has the following structure. [ka]

[0096] The term "compound of formula (III)" refers to 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, which has the following structure. [ka]

[0097] The term "subject" refers to animals including, but not limited to, primates (e.g., humans), cattle, sheep, goats, horses, dogs, cats, rabbits, rats, or mice. The terms "subject" and "patient" are used interchangeably in this specification when referring to mammalian subjects, such as human subjects.

[0098] The terms “to treat,” “to treat,” and “treatment” mean methods for obtaining beneficial or desired clinical outcomes. As used herein, “treatment” encompasses the administration of any therapeutic agent or application of a treatment for a disease in mammals, including humans. For the purposes of this disclosure, beneficial or desired clinical outcomes include, but are not limited to, one or more of the following: relief of one or more symptoms; reduction of disease severity; prevention or delay of disease spread (e.g., metastasis); prevention or delay of disease recurrence; delay or slowing of disease progression; improvement of disease status; inhibition of disease or disease progression; inhibition or slowing of disease or its progression; prevention of its onset; and remission (whether partial or total). Reduction of the pathological outcomes of proliferative disorders is also included in “treatment.” The methods provided herein are intended to achieve any one or more of these aspects of treatment. In accordance with the foregoing, the term “treatment” does not require the 100 percent elimination of all aspects of the disorder.

[0099] In the context of cancer, the terms “to treat,” “to treat,” and “treatment” include, but are not limited to, inhibiting the growth of cancer cells, inhibiting the replication of cancer cells, reducing the overall tumor burden, and delaying, halting, or slowing tumor growth, progression, or metastasis.

[0100] As used herein, the terms “cancer” and “tumor” refer to or represent a physiological condition in mammals characterized by the uncontrolled proliferation of a population of cells. This term encompasses solid tumors and hematological / lymphoid cancers. Examples of cancer include, but are not limited to, DNA repair pathway deficiency cancers and homologous recombination deficiency (HRD) cancers. Other examples of cancer include, but are not limited to, ovarian cancer, breast cancer (including triple-negative breast cancer), non-small cell lung cancer (NSCLC), and osteosarcoma. Cancer may be BRCA1 and / or BRCA2 wild-type. Cancer may also be BRCA1 and / or BRCA2 mutant. Cancer may further be PARP inhibitor-refractory or resistant cancer, or PARP inhibitor-refractory or resistant BRCA1-mutated or BRCA2-mutated cancer.

[0101] As used herein, the terms “disease,” “condition,” or “disorder” refer to a condition requiring and / or desired treatment, and mean, in principle, a disorder and / or abnormality that is considered a pathological state or function, which may manifest in the form of specific signs, symptoms and / or functional impairments. As shown below, the compounds of this disclosure can be used in the treatment of diseases and conditions such as proliferative disorders like cancer.

[0102] The "therapeutically effective dose" of a substance may vary depending on factors such as the individual's disease state, age, sex, and weight, as well as the substance's ability to elicit the desired response in the individual. The therapeutically effective dose is also the amount in which the therapeutically beneficial effect outweighs any toxic or harmful effects of the substance. The therapeutically effective dose may be delivered in one or more doses. The therapeutically effective dose refers to the effective amount in the dosage and duration required to achieve the desired therapeutic effect.

[0103] The terms "administer," "give delivery," and "give delivery" refer to methods that can be used to enable the delivery of a therapeutic agent to the desired biological site of action. For information on administration techniques that can be used with the agents and methods described herein, see, for example, Goodman and Gilman, *The Pharmacological Basis of Therapeutics*, current ed.; Pergamon; and Remington's, *Pharmaceutical Sciences* (current edition), Mack Publishing Co., Easton, Pa.

[0104] The terms "pharmaceutical preparation" and "pharmaceutical composition" refer to preparations that are in a form that allows the biological activity of the active ingredient(s) to be effective, and that do not contain any other ingredients that are unacceptably toxic to the subject to whom the preparation will be administered. Such preparations may be sterilized.

[0105] The terms “pharmaceutically acceptable carrier,” “pharmaceutically acceptable excipient,” “physiologically acceptable carrier,” or “physiologically acceptable excipient” refer to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. A pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration used and is compatible with other components of the formulation. A pharmaceutically acceptable carrier is appropriate for the formulation in which it is used. In one embodiment, each component is “pharmaceutically acceptable” in the sense that it is compatible with other components of the pharmaceutical formulation and is suitable for use in contact with human and animal tissues or organs without excessive toxicity, irritation, allergic reactions, immunogenicity, or other problems or complications, and is commensurate with a reasonable benefit / risk ratio. See Remington: The Science and Practice of Pharmacy, 21st Edition, Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 5th Edition, Rowe et al., Eds., The Pharmaceutical Press and the American Pharmaceutical Association: 2005; and Handbook of Pharmaceutical Additives, 3rd Edition, Ash and Ash Eds., Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, Gibson Ed., CRC Press LLC: Boca Raton, FL, 2004 (incorporated herein by reference).

[0106] As used herein, the term “about” includes ±10% of the number given. Thus, “about 10” means 9 to 11. As will be understood by those skilled in the art, any reference to a “about” value or parameter herein includes (and describes) specific examples relating to that value or parameter itself. For example, any description referring to “about X” includes a description of “X.”

[0107] The terms “active ingredient” and “active substance” refer to compounds administered to a subject, alone or in combination with one or more pharmaceutically acceptable excipients, to treat, prevent, or alleviate one or more symptoms of a condition, disorder, or disease. As used herein, “active ingredient” and “active substance” may be optically active isomers of the compounds described herein.

[0108] The terms “drug,” “therapeutic agent,” and “chemotherapeutic agent” refer to a compound or its pharmaceutical composition administered to a subject to treat, prevent, or alleviate one or more symptoms of a condition, disorder, or disease.

[0109] The term "solvate" refers to a compound or a salt thereof provided herein, which further comprises a stoichiometric or non-stoichiometric amount of solvent bonded by non-covalent intermolecular forces. If the solvent is water, the solvate is a hydrate. If the solvent contains ethanol, the compound may be an ethanol solvate.

[0110] As used herein, the term "polymorph" refers to a crystalline form of a compound or its salt, hydrate, or solvate in a particular crystal lattice arrangement. All polymorphs have the same elemental composition. As used herein, the term "crystalline" refers to a solid form in which structural units are regularly arranged. Different crystalline forms of the same compound, or its salt, cocrystal, hydrate, or solvate, arise from different arrangements of molecules in the solid state, resulting in different crystal symmetries and / or unit cell parameters. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystal shape, optical and electrical properties, stability, and solubility. For example, Remington's Pharmaceutical Sciences, 18 th ed.,Mack Publishing,Easton PA,173 (1990);The United States Pharmacopeia,23 rd See ed., 1843–1844 (1995) (as incorporated herein by reference).

[0111] Crystal morphology is most commonly characterized by X-ray powder diffraction (XRPD). The XRPD pattern of reflections (peaks, typically represented by an angle of 2θ) is generally considered a fingerprint of a particular crystal morphology. The relative intensity of XRPD peaks can vary widely, particularly depending on the sample preparation technique, crystal size distribution, filters, sample mounting procedure, and the specific instrument used. In some cases, new peaks may be observed or existing peaks may disappear, depending on the type or setting of the instrument. In some cases, certain peaks in the XRPD pattern may appear as singlets, doublets, triplets, quartets, or multiplets, depending on the type or setting of the instrument, the sensitivity of the instrument, the measurement conditions, and / or the purity of the crystal morphology. In some cases, any particular peak in the XRPD pattern may appear symmetrically or asymmetrically, and may have, for example, shoulders. Those skilled in the art who understand these variations can identify or confirm the distinct features or properties of a particular crystal morphology using not only XRPD but also other known physicochemical techniques.

[0112] The term "amorphous," applied to compounds, refers to a state in which a substance lacks long-range order at the molecular level and can exhibit solid or liquid physical properties depending on temperature. Typically, such substances do not exhibit a characteristic X-ray diffraction pattern and exhibit solid properties, but are more formally described as liquids. Upon heating, a change of state occurs, typically characterized by a second-order transition ("glass transition"), from solid to liquid properties.

[0113] The term "anhydrous," applied to compounds, refers to a solid state in which the compound does not contain structural water within its crystal lattice.

[0114] Unless the context requires otherwise, the terms “comprise,” “comprises,” and “comprising” should be used in accordance with the standard and clear understanding and should be interpreted comprehensively, not exclusively, and the applicant intends that each of these terms should be interpreted comprehensively, not exclusively, when interpreting the Patent, including the attached claims.

[0115] II. Solid form This disclosure relates to the solid forms of the compound of formula (I), the compound of formula (II), and the compound of formula (III). As with all pharmaceutical compounds and compositions, the chemical and physical properties of the compound of formula (I), the compound of formula (II), and the compound of formula (III) are important in their commercial development. These properties include, but are not limited to, (1) packing properties such as molar volume, volume density, and hygroscopicity; (2) thermodynamic properties such as melting temperature, vapor pressure, and solubility; (3) reaction rate properties such as dissolution rate and stability (including stability under ambient conditions, particularly with respect to moisture, and stability under storage conditions); (4) surface properties such as surface area, wettability, interfacial tension, and shape; (5) mechanical properties such as hardness, tensile strength, moldability, handling, flow, and mixability; and (6) filtration properties. These properties may, for example, affect the handling and storage of the compound and pharmaceutical compositions containing the compound.

[0116] The solid forms of the compounds of formula (I), formula (II), and formula (III) are desirable to exhibit one or more improvements in these properties compared to other solid forms of the compounds. Isolating pharmaceutically acceptable solid forms of compounds that can be manufactured or formulated on a commercial scale has been challenging until now.

[0117] A. Compounds of formula (II) In one embodiment, the present disclosure relates to the solid form of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), [ka] or relating to a pharmaceutically acceptable salt thereof.

[0118] In some embodiments, the solid form is the amorphous form of the compound of formula (II). In some embodiments, the amorphous form is a hydrate, an anhydride, or a solvate thereof. In some embodiments, the amorphous form substantially does not include other polymorphic forms.

[0119] In some embodiments, the disclosure relates to mixtures comprising an amorphous form, with the majority being an amorphous form compared to other solid forms of the compound of formula (II). In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0120] In some embodiments, the solid form is the crystalline form of the compound of formula (II). In some embodiments, the crystalline form is the hydrate, anhydrous, or solvate thereof. In some embodiments, the solvate is the dichloromethane solvate.

[0121] In some embodiments, the solid form of the compound of formula (II) is a) Crystal morphology A, characterized by an XRPD pattern having peaks at 14.3±0.2°, 21.5±0.2°, and 21.8±0.2°²θ; b) Crystal morphology C characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, and 19.1±0.2°²θ; c) Crystal morphology D, characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, and 19.3±0.2°²θ; d) Crystal morphology E characterized by an XRPD pattern having peaks at 10.6±0.2°, 18.7±0.2°, and 20.9±0.2°²θ; and, (e) Crystal morphology F, characterized by an XRPD pattern having peaks at 10.7±0.2°, 14.3±0.2°, and 21.8±0.2°²θ, It is selected from the group consisting of the following.

[0122] In some embodiments, the solid form of the compound of formula (II) is a) Crystal morphology A, characterized by an XRPD pattern having peaks at 14.3±0.2°, 21.5±0.2°, and 21.8±0.2°²θ; b) Crystal morphology C characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, and 19.1±0.2°²θ; c) Crystal morphology D, characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, and 19.3±0.2°²θ; and d) Crystal morphology E characterized by an XRPD pattern having peaks at 10.6±0.2°, 18.7±0.2°, and 20.9±0.2°²θ, It is selected from the group consisting of the following.

[0123] In some embodiments, the solid form is a pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). In some embodiments, the pharmaceutically acceptable salt is formed between 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a pharmaceutically acceptable acid.

[0124] In some embodiments, pharmaceutically acceptable acids include 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, and The acid is selected from the group consisting of tansulfonic acid, mucoic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, the benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with two hydroxyl groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with three hydroxyl groups is gallic acid.In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, the pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, the pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.

[0125] In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is in an amorphous form. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0126] In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is in crystalline form.

[0127] In some embodiments, pharmaceutically acceptable salts of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) are its hydrate, anhydrous, or solvate.

[0128] In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a hydrochloride. In some embodiments, the hydrochloride is crystalline form 1 characterized by an XRPD pattern having peaks at 12.5±0.2°, 22.4±0.2°, and 23.9±0.2°²θ. In some embodiments, the hydrochloride is crystalline form 1 characterized by an XRPD pattern as shown in Figure 7.

[0129] In some embodiments, the hydrochloride of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a crystalline form 3 characterized by an XRPD pattern as shown in Figure 15.

[0130] In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a hydrobromide. In some embodiments, the hydrobromide is a crystalline form 4 characterized by an XRPD pattern as shown in Figure 16.

[0131] In some embodiments, the hydrobromide of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a crystalline form characterized by an XRPD pattern as shown in Figure 17.

[0132] In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is ethanedisulfonate. In some embodiments, the ethanedisulfonate is crystalline form 6 characterized by an XRPD pattern as shown in Figure 18.

[0133] In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a methanesulfonate. In some embodiments, the methanesulfonate is a crystalline form 7 characterized by an XRPD pattern as shown in Figure 19.

[0134] In some embodiments, the solid form is a pharmaceutically acceptable cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a second pharmaceutically acceptable compound. In some embodiments, the second pharmaceutically acceptable compound is a pharmaceutically acceptable acid. In some embodiments, the pharmaceutically acceptable cocrystal is formed between 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a pharmaceutically acceptable acid.

[0135] In some embodiments, pharmaceutically acceptable acids include 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, and The acid is selected from the group consisting of tansulfonic acid, mucoic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, the benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with two hydroxyl groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with three hydroxyl groups is gallic acid.In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is hydrobromic acid. In some embodiments, the pharmaceutically acceptable acid is ethanedisulfonic acid. In some embodiments, the pharmaceutically acceptable acid is methanesulfonic acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.

[0136] In some embodiments, the pharmaceutically acceptable cocrystals of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) are its hydrate, anhydrous, or solvate.

[0137] In some embodiments, the pharmaceutically acceptable cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is the gentisic acid cocrystal. In some embodiments, the gentisic acid cocrystal is a crystalline morphology characterized by an XRPD pattern having peaks at 16.6±0.2°, 18.7±0.2°, and 22.5±0.2°²θ.

[0138] In some embodiments, the pharmaceutically acceptable cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a benzoic acid cocrystal. In some embodiments, the benzoic acid cocrystal is a crystalline morphology characterized by an XRPD pattern having peaks at 12.1±0.2°, 14.2±0.2°, and 16.5±0.2°²θ. In some embodiments, the pharmaceutically acceptable cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) is a salicylic acid cocrystal. In some embodiments, the salicylic acid cocrystal is a crystalline form substantially characterized by an XRPD pattern as shown in Figure 33.

[0139] In the following chapters, we will discuss the solid forms of the compound of formula (II), but the characteristics of these solid forms have already been identified and selected.

[0140] 1.Crystal form A In one embodiment, the present disclosure relates to crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0141] In some embodiments, crystalline form A is 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrate.

[0142] In some embodiments, the melting point of crystalline form A is approximately 165°C.

[0143] In some embodiments, crystal morphology A is characterized by an XRPD pattern having peaks at 14.3±0.2°, 21.5±0.2°, and 21.8±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystal morphology A is characterized by an XRPD pattern having peaks at 7.1±0.2°, 14.3±0.2°, 21.5±0.2°, and 21.8±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, crystal morphology A is characterized by an XRPD pattern having peaks at 7.1±0.2°, 14.3±0.2°, 19.1±0.2°, 21.5±0.2°, and 21.8±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystalline morphology A is characterized by an XRPD pattern having peaks at 7.1±0.2°, 14.3±0.2°, 15.2±0.2°, 19.1±0.2°, 21.5±0.2°, and 21.8±0.2°²θ when measured by Cu Kα radiation.

[0144] In some embodiments, crystalline morphology A is substantially characterized by an XRPD pattern as shown in Figure 1.

[0145] In some embodiments, crystalline morphology A is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 1 below. [Table 1] [Table 2]

[0146] In some embodiments, crystalline morphology A is characterized by an endothermic peak at approximately 162°C to 168°C, or approximately 163°C to 167°C, or approximately 164°C to 166°C, as measured by DSC. In some embodiments, crystalline morphology A is characterized by an endothermic peak at approximately 165°C, as measured by DSC.

[0147] In some embodiments, crystalline morphology A is substantially characterized by a DSC profile as shown in Figure 2.

[0148] In some embodiments, crystalline morphology A is characterized by a decrease of about 0.88% to about 0.98% by weight between room temperature and about 150°C. In some embodiments, crystalline morphology A is characterized by a decrease of about 0.90% to about 0.96% by weight between room temperature and about 150°C. In some embodiments, crystalline morphology A is characterized by a decrease of about 0.93% by weight between room temperature and about 150°C.

[0149] In some embodiments, crystalline morphology A is substantially characterized by a TGA profile as shown in Figure 2.

[0150] In some embodiments, the crystal morphology A is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 1, b) a DSC profile as shown in Figure 2, or c) a TGA profile as shown in Figure 2.

[0151] In some embodiments, crystal morphology A has a unit cell that is classified as a monoclinic system.

[0152] In some embodiments, crystalline form A has a unit cell with an a value of approximately 12.054 Å, a b value of approximately 8.775 Å, and a c value of approximately 24.837 Å. In other embodiments, form A has a volume of approximately 2603.68 Å. 3 It has a unit cell.

[0153] In some embodiments, crystalline form A substantially does not contain other polymorphic forms. In some embodiments, crystalline form A has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. In some embodiments, crystalline form A has a polymorphic purity of at least 80%.

[0154] In another embodiment, the disclosure relates to a mixture comprising crystalline form A and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form C, or crystalline form D, or crystalline form F, or crystalline form 1, or crystalline form 2.

[0155] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (II) is in crystalline form A compared to other solid forms.

[0156] 2.Crystal form C In one embodiment, the present disclosure relates to the crystalline form C of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0157] In some embodiments, the crystalline form C is anhydrous.

[0158] In some embodiments, the crystal morphology C is characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, and 19.1±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology C is characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, 19.1±0.2°, and 21.5±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, the crystal morphology C is characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, 19.1±0.2°, 19.8±0.2°, and 21.5±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystalline morphology C is characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, 19.1±0.2°, 19.8±0.2°, 21.5±0.2°, and 21.8±0.2°²θ when measured by Cu Kα radiation.

[0159] In some embodiments, the crystalline morphology C is substantially characterized by an XRPD pattern as shown in Figure 3.

[0160] In some embodiments, the crystalline morphology C is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 2 below. [Table 3] [Table 4]

[0161] In some embodiments, crystalline form C is substantially free of other polymorphic forms. In some embodiments, crystalline form C has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0162] In another embodiment, the disclosure relates to a mixture comprising crystalline form C and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form D, or crystalline form E, or crystalline form 1, or crystalline form 2.

[0163] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (II) is in crystalline form C compared to other solid forms.

[0164] 3.Crystal form D In one embodiment, the present disclosure relates to the crystalline form D of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0165] In some embodiments, the crystalline form D is anhydrous.

[0166] In some embodiments, crystalline morphology D is characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, and 19.3±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystalline morphology D is characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, 16.4±0.2°, and 19.3±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, crystalline morphology D is characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, 16.4±0.2°, 19.3±0.2°, and 20.9±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology D is characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, 16.4±0.2°, 19.3±0.2°, 20.9±0.2°, and 21.6±0.2°²θ when measured by Cu Kα radiation.

[0167] In some embodiments, the crystal morphology D is substantially characterized by an XRPD pattern as shown in Figure 4.

[0168] In some embodiments, the crystal morphology D is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 2 below. [Table 5] [Table 6]

[0169] In some embodiments, crystalline form D substantially does not contain other polymorphic forms. In some embodiments, crystalline form D has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0170] In another embodiment, the disclosure relates to a mixture comprising crystalline form D and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form E, or crystalline form 1, or crystalline form 2.

[0171] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (II) is in crystalline form D compared to other solid forms.

[0172] 4.Crystal form E In one embodiment, the present disclosure relates to the crystalline form E of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0173] In some embodiments, crystalline form E is a solvate. In some embodiments, crystalline form E is a dichloromethane solvate.

[0174] In some embodiments, the melting point of crystalline form E is approximately 107°C.

[0175] In some embodiments, the crystal morphology E is characterized by an XRPD pattern having peaks at 10.6±0.2°, 18.7±0.2°, and 20.9±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology E is characterized by an XRPD pattern having peaks at 10.6±0.2°, 18.7±0.2°, 20.9±0.2°, and 21.2±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, the crystal morphology E is characterized by an XRPD pattern having peaks at 10.6±0.2°, 16.4±0.2°, 18.7±0.2°, 20.9±0.2°, and 21.2±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology E is characterized by an XRPD pattern having peaks at 10.6±0.2°, 16.4±0.2°, 18.7±0.2°, 20.9±0.2°, 21.2±0.2°, and 23.9±0.2°²θ when measured by Cu Kα radiation.

[0176] In some embodiments, the crystalline morphology E is substantially characterized by an XRPD pattern as shown in Figure 5.

[0177] In some embodiments, the crystalline morphology E is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 4 below. [Table 7]

[0178] In some embodiments, the crystal morphology E is characterized by an endothermic peak at approximately 102°C to 112°C, or approximately 104°C to 110°C, or approximately 106°C to 108°C, as measured by DSC. In some embodiments, the crystal morphology E is characterized by an endothermic peak at approximately 107°C, as measured by DSC.

[0179] In some embodiments, the crystalline morphology E is substantially characterized by a DSC profile as shown in Figure 6.

[0180] In some embodiments, crystalline morphology E is characterized by a decrease of about 13.0% to about 14.0% by weight between room temperature and about 200°C. In some embodiments, crystalline morphology E is characterized by a decrease of about 13.2% to about 13.8% by weight between room temperature and about 200°C. In some embodiments, crystalline morphology E is characterized by a decrease of about 13.5% by weight between room temperature and about 200°C.

[0181] In some embodiments, the crystalline morphology E is substantially characterized by a TGA profile as shown in Figure 6.

[0182] In some embodiments, the crystalline morphology E is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 5, b) a DSC profile as shown in Figure 6, or c) a TGA profile as shown in Figure 6.

[0183] In some embodiments, crystalline form E substantially does not contain other polymorphic forms. In some embodiments, crystalline form E has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0184] In another embodiment, the disclosure relates to a mixture comprising crystalline form E and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form 1, or crystalline form 2.

[0185] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (II) is in crystalline form E compared to other solid forms.

[0186] 5.Crystal form F In one embodiment, the present disclosure relates to the crystalline form F of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0187] In some embodiments, the crystalline form F is anhydrous.

[0188] In some embodiments, the crystal morphology F is characterized by an XRPD pattern having peaks at 10.7±0.2°, 14.3±0.2°, and 21.8±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology F is characterized by an XRPD pattern having peaks at 10.7±0.2°, 14.3±0.2°, 21.5±0.2°, and 21.8±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, the crystal morphology F is characterized by an XRPD pattern having peaks at 10.7±0.2°, 14.3±0.2°, 15.8±0.2°, 21.5±0.2°, and 21.8±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology F is characterized by an XRPD pattern having peaks at 10.7±0.2°, 14.3±0.2°, 15.8±0.2°, 21.5±0.2°, 21.8±0.2°, and 25.0±0.2°²θ when measured by Cu Kα radiation.

[0189] In some embodiments, the crystalline morphology F is substantially characterized by an XRPD pattern as shown in Figure 25.

[0190] In some embodiments, the crystalline morphology F is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 5 below. [Table 8] [Table 9-1] [Table 9-2]

[0191] In some embodiments, the crystal morphology F is characterized by an endothermic peak at approximately 153°C to 160°C, or approximately 154°C to 159°C, or approximately 155°C to 158°C, as measured by DSC. In some embodiments, the crystal morphology F is characterized by an endothermic peak at approximately 157°C, as measured by DSC.

[0192] In some embodiments, the crystalline morphology F is substantially characterized by a DSC profile as shown in Figure 26.

[0193] In some embodiments, the crystalline morphology F is characterized by at least one of the following: a) an XRPD pattern as shown in Figure 25, or b) a DSC profile as shown in Figure 26.

[0194] In some embodiments, the crystalline form F is substantially free of other polymorphic forms. In some embodiments, the crystalline form F has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0195] In another embodiment, the disclosure relates to a mixture comprising crystalline form F and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form 1, or crystalline form 2, or crystalline form 8, or crystalline form 9.

[0196] In some embodiments, the present disclosure relates to a mixture comprising mostly crystalline form F compared to other solid forms of the compound of formula (II).

[0197] 6. Crystal Form 1 In one aspect, the present disclosure relates to Crystal Form 1 of the hydrochloride salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II).

Chemical Structure

[0198] In some embodiments, Crystal Form 1 is 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride hydrate.

[0199] In some embodiments, the melting point of Crystal Form 1 is from about 140 °C to about 145 °C. In some embodiments, the melting point of Crystal Form 1 is from about 140 °C to about 143 °C. In some embodiments, the melting point of Crystal Form 1 is about 140.8 °C.

[0200] In some embodiments, crystal morphology 1 is characterized by an XRPD pattern having peaks at 12.5±0.2°, 22.4±0.2°, and 23.9±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystal morphology 1 is characterized by an XRPD pattern having peaks at 12.5±0.2°, 17.2±0.2°, 22.4±0.2°, and 23.9±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, crystal morphology 1 is characterized by an XRPD pattern having peaks at 12.5±0.2°, 17.2±0.2°, 19.7±0.2°, 22.4±0.2°, and 23.9±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystal morphology 1 is characterized by an XRPD pattern having peaks at 12.5±0.2°, 17.2±0.2°, 19.7±0.2°, 22.4±0.2°, 23.1±0.2°, and 23.9±0.2°²θ when measured by Cu Kα radiation.

[0201] In some embodiments, the crystal morphology 1 is substantially characterized by an XRPD pattern as shown in Figure 7.

[0202] In some embodiments, crystalline morphology 1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 6 below. [Table 10]

[0203] In some embodiments, crystal morphology 1 is characterized by an endothermic peak at approximately 136°C to 146°C, or approximately 138°C to 144°C, or approximately 140°C to 143°C, as measured by DSC. In some embodiments, crystal morphology 1 is characterized by an endothermic peak at approximately 142.1°C, as measured by DSC.

[0204] In some embodiments, crystalline morphology 1 is substantially characterized by a DSC profile as shown in Figure 8.

[0205] In some embodiments, crystalline morphology 1 is characterized by a decrease of about 3.0% to about 5.0% by weight between about 30°C and about 100°C. In some embodiments, crystalline morphology 1 is characterized by a decrease of about 3.5% to about 4.5% by weight between about 30°C and about 100°C. In some embodiments, crystalline morphology 1 is characterized by a decrease of about 4.04% by weight between about 30°C and about 100°C.

[0206] In some embodiments, crystalline morphology 1 is substantially characterized by a TGA profile as shown in Figure 8.

[0207] In some embodiments, crystalline morphology 1 is characterized by a decrease of about 12.0% to about 14.0% by weight between room temperature and about 180°C. In some embodiments, crystalline morphology 1 is characterized by a decrease of about 12.8% to about 13.4% by weight between room temperature and about 180°C. In some embodiments, crystalline morphology 1 is characterized by a decrease of about 13.13% by weight between room temperature and about 180°C.

[0208] In some embodiments, the crystal morphology 1 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 7, b) a DSC profile as shown in Figure 8, or c) a TGA profile as shown in Figure 8.

[0209] In some embodiments, crystalline form 1 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0210] In another aspect, the present disclosure relates to a mixture comprising crystalline form 1 and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 2, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form 2.

[0211] In some embodiments, the present disclosure relates to a mixture comprising predominantly crystalline form 1 as compared to other solid forms of the compound of formula (II).

[0212] 7. Crystalline form 2 In one aspect, the present disclosure relates to crystalline form 2 of the gentisic acid co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [Chemical formula]

[0213] In some embodiments, crystalline form 2 is an anhydride.

[0214] In some embodiments, the melting point of crystalline form 2 is from about 184 °C to about 190 °C. In some embodiments, the melting point of crystalline form 2 is from about 186 °C to about 188 °C. In some embodiments, the melting point of crystalline form 2 is about 187 °C.

[0215] In some embodiments, crystal morphology 2 is characterized by an XRPD pattern having peaks at 16.6±0.2°, 18.7±0.2°, and 22.5±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystal morphology 2 is characterized by an XRPD pattern having peaks at 16.6±0.2°, 18.7±0.2°, 22.3±0.2°, and 22.5±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, crystal morphology 2 is characterized by an XRPD pattern having peaks at 16.6±0.2°, 18.7±0.2°, 22.3±0.2°, 22.5±0.2°, and 26.0±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystalline morphology 2 is characterized by an XRPD pattern having peaks at 16.6±0.2°, 18.7±0.2°, 20.8±0.2°, 22.3±0.2°, 22.5±0.2°, and 26.0±0.2°²θ when measured by Cu Kα radiation.

[0216] In some embodiments, the crystal morphology 2 is substantially characterized by an XRPD pattern as shown in Figure 9.

[0217] In some embodiments, crystalline morphology 2 is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 7 below. [Table 11] [Table 12]

[0218] In some embodiments, crystal morphology 2 is characterized by an endothermic peak at approximately 181°C to 191°C, or approximately 183°C to 189°C, or approximately 185°C to 187°C, as measured by DSC. In some embodiments, crystal morphology 2 is characterized by an endothermic peak at approximately 186.0°C, as measured by DSC.

[0219] In some embodiments, crystalline morphology 2 is substantially characterized by a DSC profile as shown in Figure 10.

[0220] In some embodiments, crystalline form 2 is characterized by a decrease of about 2.5% to about 3.5% by weight between room temperature and about 170°C. In some embodiments, crystalline form 2 is characterized by a decrease of about 3.0% to about 3.4% by weight between room temperature and about 170°C. In some embodiments, crystalline form 2 is characterized by a decrease of about 3.17% by weight between room temperature and about 170°C.

[0221] In some embodiments, crystalline morphology 2 is substantially characterized by a TGA profile as shown in Figure 10.

[0222] In some embodiments, the crystal morphology 2 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 9, b) a DSC profile as shown in Figure 10, or c) a TGA profile as shown in Figure 10.

[0223] In some embodiments, the crystal morphology 2 has a unit cell that is classified as a monoclinic system.

[0224] In some embodiments, crystalline form 2 has a unit cell with an a value of approximately 11.113 Å, a b value of approximately 12.356 Å, and a c value of approximately 24.048 Å. In some embodiments, form 2 has a volume of approximately 3223.93 Å. 3 It has a unit cell.

[0225] The unit cell parameters for crystal form 2 are as follows: [Table 13]

[0226] In some embodiments, crystalline form 2 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 2 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0227] In another embodiment, the disclosure relates to a mixture comprising crystalline form 2 and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 8, or crystalline form 9. In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form 1.

[0228] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (II) is in crystalline form 2 compared to other solid forms.

[0229] Crystal morphology 2 exhibits unexpected chemical and physical properties, as well as advantageous bioavailability characteristics compared to the free base morphology. In particular, as shown in Figure 21, 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid of formula (II) exhibit significant hydrogen bonding interactions, despite being interactions between a weak base and a weak acid, respectively.

[0230] Furthermore, as shown in Example 14, crystalline form 2 surprisingly shows increased oral exposure levels in mice compared to other solid forms of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). For example, as shown in Example 14, in some embodiments, crystalline form 2 (gentisic acid cocrystal) shows a higher exposure level of about 300 mg / kg than crystalline form A (free base).

[0231] 8. Crystal Form 3 In another aspect, the present disclosure relates to a crystalline form 3 of the hydrochloride salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0232] In some embodiments, crystalline morphology 3 is substantially characterized by an XRPD pattern as shown in Figure 15.

[0233] 9. Crystal Form 4 In another aspect, the present disclosure relates to a crystalline form 4 of the hydrobromide salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0234] In some embodiments, the crystalline morphology 4 is substantially characterized by an XRPD pattern as shown in Figure 16.

[0235] 10. Crystal Form 5 In another aspect, the present disclosure relates to a crystalline form 5 of the hydrobromide salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0236] In some embodiments, the crystal morphology 5 is substantially characterized by an XRPD pattern as shown in Figure 17.

[0237] 11. Crystal Form 6 In another aspect, the present disclosure relates to crystalline form 6 of the ethane disulfonate of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0238] In some embodiments, the crystal morphology 6 is substantially characterized by an XRPD pattern as shown in Figure 18.

[0239] 12. Crystal Form 7 In another aspect, the present disclosure relates to the crystalline form 7 of the methanesulfonate of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0240] In some embodiments, the crystal morphology 7 is substantially characterized by an XRPD pattern as shown in Figure 19.

[0241] 13. Crystal Form 8 In one embodiment, the present disclosure relates to the crystalline form 8 of a benzoic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0242] In some embodiments, the crystalline form 8 is anhydrous.

[0243] In some embodiments, the melting point of crystalline form 8 is about 100°C to about 110°C. In some embodiments, the melting point of crystalline form 8 is about 102°C to about 108°C. In some embodiments, the melting point of crystalline form 8 is about 105°C.

[0244] In some embodiments, the crystal morphology 8 is characterized by an XRPD pattern having peaks at 12.1±0.2°, 14.2±0.2°, and 16.5±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology 8 is characterized by an XRPD pattern having peaks at 12.1±0.2°, 16.5±0.2°, 19.0±0.2°, and 21.0±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, the crystal morphology 8 is characterized by an XRPD pattern having peaks at 12.1±0.2°, 14.2±0.2°, 16.5±0.2°, and 21.0±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology 8 is characterized by an XRPD pattern having peaks at 12.1±0.2°, 16.5±0.2°, 21.0±0.2°, 23.0±0.2°, and 25.7±0.2°²θ when measured by Cu Kα radiation.

[0245] In some embodiments, the crystal morphology 8 is substantially characterized by an XRPD pattern as shown in Figure 29.

[0246] In some embodiments, the crystal morphology 8 is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 8 below. [Table 14-1] [Table 14-2]

[0247] In some embodiments, the crystal morphology 8 is characterized by an endothermic peak at approximately 100°C to 110°C, or approximately 102°C to 108°C, or approximately 104°C to 106°C, as measured by DSC. In some embodiments, the crystal morphology 8 is characterized by an endothermic peak at approximately 105.3°C, as measured by DSC.

[0248] In some embodiments, the crystal morphology 8 is substantially characterized by a DSC profile as shown in Figure 30.

[0249] In some embodiments, crystalline morphology 8 is characterized by a decrease of about 14% to about 24% by weight between about 120°C and about 300°C. In some embodiments, crystalline morphology 8 is characterized by a decrease of about 16% to about 20% by weight between about 120°C and about 300°C. In some embodiments, crystalline morphology 8 is characterized by a decrease of about 18% to about 19% by weight between about 120°C and about 300°C. In some embodiments, crystalline morphology 8 is characterized by a decrease of about 18.8% by weight between about 120°C and about 300°C.

[0250] In some embodiments, the crystal morphology 8 is substantially characterized by a TG-FTIR profile as shown in Figure 31.

[0251] In some embodiments, the crystal morphology 8 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 29, b) a DSC profile as shown in Figure 30, or c) a TG-FTIR profile as shown in Figure 31.

[0252] In some embodiments, the crystal morphology 8 has a unit cell that is classified as a monoclinic system.

[0253] In some embodiments, crystalline form 8 has a unit cell with an a value of approximately 10.61070(10) Å, a b value of approximately 12.39940(10) Å, and a c value of approximately 24.15170(10) Å. In other embodiments, form 8 has a volume of approximately 3114.74(4) Å. 3 It has a unit cell.

[0254] The unit cell parameters for crystal form 8 are as follows: [Table 15]

[0255] In some embodiments, crystalline form 8 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 8 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0256] In another embodiment, the disclosure relates to a mixture comprising crystalline form 8 and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 9.

[0257] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (II) is in crystalline form 8 compared to other solid forms.

[0258] 14. Crystal Form 9 In one embodiment, the present disclosure relates to a crystalline form 9 of a salicylic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). [ka]

[0259] In some embodiments, the crystalline form 9 is anhydrous.

[0260] In some embodiments, the crystal morphology 9 is characterized by an XRPD pattern having peaks at 11.0±0.2°, 16.5±0.2°, and 25.3±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology 9 is characterized by an XRPD pattern having peaks at 11.0±0.2°, 16.5±0.2°, 17.3±0.2°, and 25.3±0.2°²θ when measured with Cu Kα radiation.

[0261] In some embodiments, the crystal morphology 9 is substantially characterized by an XRPD pattern as shown in Figure 33.

[0262] In some embodiments, the crystal morphology 9 is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 9 below. [Table 16-1] [Table 16-2] [Table 16-3]

[0263] In some embodiments, the crystal morphology 9 is as shown in Figure 34. 1 It is essentially characterized by its 1H NMR profile.

[0264] In some embodiments, the crystal morphology 9 is a) an XRPD pattern as shown in Figure 33, or b) as shown in Figure 34. 1 Characterized by at least one of the 1H NMR profiles.

[0265] In some embodiments, the crystal morphology 9 has a unit cell that is classified as a monoclinic system.

[0266] In some embodiments, crystalline form 9 has a unit cell with an a value of approximately 10.8387(11) Å, a b value of approximately 12.3761(12) Å, and a c value of approximately 24.242(2) Å. In other embodiments, form 9 has a volume of approximately 3173.1(5) Å. 3 It has a unit cell.

[0267] The unit cell parameters for crystal form 9 are as follows: [Table 17]

[0268] In some embodiments, crystalline form 9 substantially does not contain other polymorphic forms. In some embodiments, crystalline form 9 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0269] In another embodiment, the present disclosure relates to a mixture comprising crystalline form 9 and a second solid form of the compound of formula (II). In some embodiments, the second solid form of the compound of formula (II) is crystalline form A, or crystalline form C, or crystalline form D, or crystalline form E, or crystalline form F, or crystalline form 1, or crystalline form 2, or crystalline form 8.

[0270] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (II) is in crystalline form 9 compared to other solid forms.

[0271] B. Compounds of formula (III) In one embodiment, the present disclosure relates to the solid form of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), [ka] or relating to a pharmaceutically acceptable salt thereof.

[0272] In some embodiments, the solid form is the amorphous form of the compound of formula (III). In some embodiments, the amorphous form is a hydrate, an anhydride, or a solvate thereof. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0273] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (III) is in an amorphous form compared to other solid forms.

[0274] In some embodiments, the solid form is the crystalline form of the compound of formula (III). In some embodiments, the crystalline form is the hydrate, anhydrous, or solvate thereof.

[0275] In some embodiments, the solid form of the compound of formula (III) is a) Crystal morphology A1 characterized by an XRPD pattern having peaks at 16.1±0.2°, 16.7±0.2°, and 24.8±0.2°²θ; b) Crystal morphology B1, characterized by an XRPD pattern having peaks at 12.9±0.2°, 14.5±0.2°, and 22.6±0.2°²θ, It is selected from the group consisting of the following.

[0276] In some embodiments, the solid form is a pharmaceutically acceptable salt or cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III). In some embodiments, the pharmaceutically acceptable salt or cocrystal is formed between 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) and a pharmaceutically acceptable acid.

[0277] In some embodiments, pharmaceutically acceptable acids include 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, and The acid is selected from the group consisting of tansulfonic acid, mucoic acid, naphthalenesulfonic acid, nicotinic acid, oxalic acid, palmitic acid, p-toluenesulfonic acid, phosphoric acid, propionic acid, saccharin, salicylic acid, stearic acid, succinic acid, sulfuric acid, L-tartaric acid, vanillic acid, vanillin, ethyl maltol, gallic acid, ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, 3,4,5-trihydroxybenzoic acid, nicotinamide, L-proline, and D-sorbitol. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, and gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one or more hydroxyl groups. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with one hydroxyl group. In some embodiments, the benzoic acid derivative substituted with one hydroxyl group is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with two hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with two hydroxyl groups is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is a benzoic acid derivative substituted with three hydroxyl groups. In some embodiments, the benzoic acid derivative substituted with three hydroxyl groups is gallic acid.In some embodiments, the benzoic acid derivative is selected from the group consisting of salicylic acid, gentisic acid, and gallic acid. In some embodiments, the pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, the pharmaceutically acceptable acid is gentisic acid. In some embodiments, the pharmaceutically acceptable acid is benzoic acid. In some embodiments, the pharmaceutically acceptable acid is salicylic acid. In some embodiments, the pharmaceutically acceptable acid is gallic acid.

[0278] In some embodiments, the pharmaceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) is in an amorphous form. In some embodiments, the amorphous form is substantially free of other polymorphic forms. In some embodiments, the amorphous form has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0279] In some embodiments, the pharmaceutically acceptable salt or cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) is in crystalline form.

[0280] In some embodiments, pharmaceutically acceptable salts or cocrystals of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) are its hydrate, anhydrous, or solvate.

[0281] In the following chapters, we will discuss the solid forms of the compound of formula (III), but the characteristics of these solid forms have already been identified and selected.

[0282] 1. Crystal morphology A1 In one embodiment, the present disclosure relates to crystalline form A1 of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III). [ka]

[0283] In some embodiments, the crystalline form A1 is anhydrous.

[0284] In some embodiments, the melting point of crystalline form A1 is approximately 148°C to approximately 152°C. In some embodiments, the melting point of crystalline form A1 is approximately 150°C to approximately 152°C. In some embodiments, the melting point of crystalline form A1 is approximately 150.5°C.

[0285] In some embodiments, crystalline morphology A1 is characterized by an XRPD pattern having peaks at 16.1±0.2°, 16.7±0.2°, and 24.8±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystalline morphology A1 is characterized by an XRPD pattern having peaks at 16.1±0.2°, 16.7±0.2°, 22.2±0.2°, and 24.8±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, crystalline morphology A1 is characterized by an XRPD pattern having peaks at 16.1±0.2°, 16.7±0.2°, 20.6±0.2°, 22.2±0.2°, and 24.8±0.2°²θ when measured with Cu Kα radiation. In another embodiment, crystalline morphology A1 is characterized by an XRPD pattern having peaks at 8.1±0.2°, 16.1±0.2°, 16.7±0.2°, 20.6±0.2°, 22.2±0.2°, and 24.8±0.2°²θ when measured by Cu Kα radiation.

[0286] In some embodiments, the crystal morphology A1 is substantially characterized by an XRPD pattern as shown in Figure 11.

[0287] In some embodiments, the crystal morphology A1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 10 below. [Table 18]

[0288] In some embodiments, crystalline morphology A1 is characterized by an endothermic peak at approximately 146°C to 154°C, or approximately 148°C to 152°C, or approximately 150°C to 152°C, as measured by DSC. In some embodiments, crystalline morphology A1 is characterized by an endothermic peak at approximately 150.5°C, as measured by DSC.

[0289] In some embodiments, the crystal morphology A1 is substantially characterized by a DSC profile as shown in Figure 12.

[0290] In some embodiments, crystalline morphology A1 is characterized by a decrease of about 0.90% to about 1.0% by weight between room temperature and about 120°C. In some embodiments, crystalline morphology A1 is characterized by a decrease of about 0.92% to about 0.98% by weight between room temperature and about 120°C. In some embodiments, crystalline morphology A1 is characterized by a decrease of about 0.95% by weight between room temperature and about 120°C.

[0291] In some embodiments, the crystal morphology A1 is substantially characterized by a TGA profile as shown in Figure 12.

[0292] In some embodiments, the crystal morphology A1 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 11, b) a DSC profile as shown in Figure 12, or c) a TGA profile as shown in Figure 12.

[0293] In some embodiments, the crystal morphology A1 has a unit cell that is classified as a monoclinic system.

[0294] In some embodiments, crystalline form A1 has a unit cell with an a value of approximately 12.545 Å, a b value of approximately 8.640 Å, and a c value of approximately 21.660 Å. In other embodiments, form A has a volume of approximately 2336.13 Å. 3 It has a unit cell.

[0295] The unit cell parameters for crystal morphology A1 are as follows: [Table 19]

[0296] In some embodiments, crystalline form A1 substantially does not contain other polymorphic forms. In some embodiments, crystalline form A1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%. In some embodiments, crystalline form A1 has a polymorphic purity of at least 80%.

[0297] In another embodiment, the disclosure relates to a mixture comprising crystalline form A1 and a second solid form of the compound of formula (III). In some embodiments, the second solid form of the compound of formula (III) is crystalline form B1.

[0298] In some embodiments, the present disclosure relates to a mixture comprising mostly crystalline form A1 compared to other solid forms of the compound of formula (III).

[0299] 2.Crystal form B1 In one embodiment, the present disclosure relates to crystalline form B1 of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III). [ka]

[0300] In some embodiments, the crystalline form B1 is anhydrous.

[0301] In some embodiments, the melting point of crystalline form B1 is approximately 160°C to approximately 164°C. In some embodiments, the melting point of crystalline form B1 is approximately 161°C to approximately 163°C. In some embodiments, the melting point of crystalline form B1 is approximately 162.1°C.

[0302] In some embodiments, the crystal morphology B1 is characterized by an XRPD pattern having peaks at 12.9±0.2°, 14.5±0.2°, and 22.6±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology B1 is characterized by an XRPD pattern having peaks at 12.9±0.2°, 14.5±0.2°, 16.7±0.2°, and 22.6±0.2°²θ when measured with Cu Kα radiation. In yet another embodiment, the crystal morphology B1 is characterized by an XRPD pattern having peaks at 12.9±0.2°, 14.5±0.2°, 16.7±0.2°, 22.6±0.2°, and 24.2±0.2°²θ when measured with Cu Kα radiation. In another embodiment, the crystal morphology B1 is characterized by an XRPD pattern with peaks at 12.9±0.2°, 14.5±0.2°, 16.7±0.2°, 20.7±0.2°, 22.6±0.2°, and 24.2±0.2°²θ when measured by Cu Kα radiation.

[0303] In some embodiments, the crystal morphology B1 is substantially characterized by an XRPD pattern as shown in Figure 13.

[0304] In some embodiments, the crystal morphology B1 is characterized by three or more, four or more, five or more, or six or more XRPD peaks as shown in Table 11 below. [Table 20]

[0305] In some embodiments, the crystal morphology B1 is characterized by an endothermic peak at approximately 156°C to 166°C, or approximately 159°C to 163°C, or approximately 160°C to 162°C, as measured by DSC. In some embodiments, the crystal morphology B1 is characterized by an endothermic peak at approximately 161.2°C, as measured by DSC.

[0306] In some embodiments, the crystal morphology B1 is substantially characterized by a DSC profile as shown in Figure 14.

[0307] In some embodiments, crystalline morphology B1 is characterized by a decrease of about 1.0% to about 2.0% by weight between room temperature and about 120°C. In some embodiments, crystalline morphology B1 is characterized by a decrease of about 1.2% to about 1.8% by weight between room temperature and about 120°C. In some embodiments, crystalline morphology B1 is characterized by a decrease of about 1.58% by weight between room temperature and about 120°C.

[0308] In some embodiments, the crystal morphology B1 is substantially characterized by a TGA profile as shown in Figure 14.

[0309] In some embodiments, the crystal morphology B1 is characterized by at least two of the following: a) an XRPD pattern as shown in Figure 13, b) a DSC profile as shown in Figure 14, or c) a TGA profile as shown in Figure 14.

[0310] In some embodiments, crystalline form B1 substantially does not contain other polymorphic forms. In some embodiments, crystalline form B1 has a polymorphic purity of at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89%, or at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%.

[0311] In another embodiment, the disclosure relates to a mixture comprising crystalline form B1 and a second solid form of the compound of formula (III). In some embodiments, the second solid form of the compound of formula (III) is crystalline form A1.

[0312] In some embodiments, the present disclosure relates to mixtures in which the majority of the compound of formula (III) is in crystalline form B1 compared to other solid forms.

[0313] III. Pharmaceutical Compositions The compounds of formula (I) disclosed herein, 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), and 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazolo-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) in solid form, as well as mixtures thereof, can be administered to mammals in the form of untreated chemicals without the presence of any other components, or the compounds of the disclosed herein can be administered to mammals as part of a pharmaceutical composition containing the compounds in combination with a suitable pharmaceutically acceptable carrier (e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and See Comparisons: Drugfacts Plus, 20th ed. (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd ed., Pharmaceutical Press (2000). Such carriers can be selected from pharmaceutically acceptable excipients and adjuvants. The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable vehicle” encompasses any of the standard pharmaceutically acceptable carriers, solvents, surfactants, or vehicles. Standard pharmaceutically acceptable carriers and their formulations are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 19th ed. 1995.

[0314] The compounds of formula (I), formula (II), and formula (III) disclosed herein in solid form, as well as mixtures thereof, may be administered to subjects via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, topical, or transdermal (e.g., by the use of transdermal patches).

[0315] In some embodiments, crystalline form A of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0316] In some embodiments, the crystalline form C of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0317] In some embodiments, crystalline form D of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0318] In some embodiments, the crystalline form E of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0319] In some embodiments, the crystalline form F of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0320] In some embodiments, the crystalline form 1 of the hydrochloride salt of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0321] In some embodiments, crystalline form 2 of the gentisinic acid cocrystal of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0322] In some embodiments, the crystalline form 3 of the hydrochloride salt of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0323] In some embodiments, the crystalline form 4 of the hydrobromide salt of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0324] In some embodiments, the crystalline form 5 of the hydrobromide salt of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0325] In some embodiments, the crystalline form 6 of the ethane disulfonate of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0326] In some embodiments, the crystalline form 7 of the methanesulfonate of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0327] In some embodiments, the crystalline form 8 of the benzoic acid cocrystal of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0328] In some embodiments, the crystalline form 9 of the salicylic acid cocrystal of the compound of formula (II) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0329] In some embodiments, the crystalline form A1 of the compound of formula (III) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0330] In some embodiments, the crystalline form B1 of the compound of formula (III) may be administered to a subject via oral, parenteral (subcutaneous, intravenous, intramuscular, intrasternal, and intravenous infusion techniques, etc.), rectal, intranasal, local, or transdermal (e.g., by the use of a patch).

[0331] In another aspect, this disclosure relates to solid dosage forms comprising one or more solid forms of the compounds of formula (I), formula (II), and formula (III) disclosed herein, and one or more pharmaceutically acceptable carriers or diluents. Examples of solid dosage forms include, but are not limited to, tablets, capsules, pills, granules, powders, sachets, chewable tablets, and films.

[0332] In some embodiments, the disclosure provides solid dosage forms comprising a compound of formula (I), a compound of formula (II), or a compound of formula (III), or pharmaceutically acceptable salts or solvates thereof, wherein the solid dosage forms are intended for use in methods of treating cancer.

[0333] In another aspect, the disclosure relates to a pharmaceutical composition comprising one or more solid forms of the compounds of formula (I), formula (II), and formula (III) disclosed herein, and one or more pharmaceutically acceptable carriers or diluents.

[0334] In some embodiments, the pharmaceutical composition comprises crystalline form A of the compound of formula (II). In some embodiments, the pharmaceutical composition comprises crystalline form C of the compound of formula (II). In some embodiments, the pharmaceutical composition comprises crystalline form D of the compound of formula (II). In some embodiments, the pharmaceutical composition comprises crystalline form E of the compound of formula (II). In some embodiments, the pharmaceutical composition comprises crystalline form F of the compound of formula (II).

[0335] In some embodiments, the pharmaceutical composition includes crystalline form 1 of the hydrochloride salt of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 2 of the gentisic acid cocrystal of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 3 of the hydrochloride salt of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 4 of the hydrobromide salt of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 5 of the hydrobromide salt of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 6 of the ethanedisulfonate salt of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 7 of the methanesulfonate salt of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 8 of the benzoic acid cocrystal of the compound of formula (II). In some embodiments, the pharmaceutical composition includes crystalline form 9 of the salicylic acid cocrystal of the compound of formula (II). In some embodiments, the pharmaceutical composition includes the amorphous form of the compound of formula (II).

[0336] In some embodiments, the pharmaceutical composition comprises a mixture of two or more solid forms of the compound of formula (II).

[0337] In some embodiments, the pharmaceutical composition comprises crystalline form A1 of the compound of formula (III). In some embodiments, the pharmaceutical composition comprises crystalline form B1 of the compound of formula (III). In some embodiments, the pharmaceutical composition comprises amorphous form of the compound of formula (III).

[0338] In some embodiments, the pharmaceutical composition comprises a mixture of two or more solid forms of the compound of formula (III).

[0339] In some embodiments, the pharmaceutical composition is an orally acceptable dosage form comprising one or more crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, and 9, as well as an amorphous form of the compound of formula (II).

[0340] In some embodiments, the pharmaceutical composition is an orally acceptable dosage form comprising one or more crystalline forms A1 and B1, as well as an amorphous form of the compound of formula (III).

[0341] In some embodiments, orally acceptable dosage forms include, but are not limited to, capsules, tablets, aqueous suspensions, and solutions.

[0342] For oral administration, known carriers may be included in the pharmaceutical composition. For example, microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate, and glycine may be used with various disintegrants such as starch (preferably corn, potato, or tapioca starch), methylcellulose, alginic acid, and certain complex silicates, and may be included in tablets together with granulating binders such as polyvinylpyrrolidone, sucrose, gelatin, and acacia. Furthermore, lubricants such as magnesium stearate, sodium lauryl sulfate, and talc are often useful for tableting. Similar types of solid compositions may also be used as fillers for gelatin capsules. In this regard, preferred materials include high molecular weight polyethylene glycol in addition to lactose or milk sugar. When aqueous suspensions and / or elixirs are desired for oral administration, the active ingredient may be mixed with various sweeteners or flavorings, colorants or dyes, and optionally, emulsifiers and / or anti-precipitation agents, along with diluents such as water, ethanol, propylene glycol, glycerin, and various similar combinations thereof.

[0343] In some embodiments, the pharmaceutical composition is a parenteral formulation comprising one or more crystalline forms A, C, D, E, F, 1, 2, 3, 4, 5, 6, 7, 8, and 9, as well as the amorphous form of the compound of formula (II).

[0344] In some embodiments, the pharmaceutical composition is a parenteral formulation comprising one or more crystalline forms A1 and B1, as well as an amorphous form of the compound of formula (III).

[0345] For parenteral administration, solutions containing the solid form of compound (I), compound (II), or compound (III) can be prepared with sesame oil or peanut oil, aqueous propylene glycol, or sterile water or physiological saline. Aqueous solutions should be appropriately buffered as needed (preferably pH greater than 8), and liquid diluents should first be isotonic with sufficient physiological saline or glucose. These aqueous solutions are suitable for intravenous injection. Oily solutions are suitable for intra-articular, intramuscular, and subcutaneous injection. Preparation of all these solutions under sterile conditions is readily carried out by standard pharmaceutical techniques well known to those skilled in the art.

[0346] In some embodiments, the pharmaceutical composition may be prepared as a liquid suspension or solution using liquids such as oil, water, alcohol, and combinations thereof.

[0347] In some embodiments, the pharmaceutical composition may be prepared for sterile injection, which may be an aqueous or oily suspension. These suspensions may be prepared according to the art known in the art.

[0348] In some embodiments, the pharmaceutical composition may be administered in the form of a suppository for rectal administration.

[0349] In some embodiments, the pharmaceutical composition may also be administered topically, particularly if the target of treatment includes areas or organs that are easily administered topically, such as diseases of the eyes, skin, or lower intestine. Topical administration to the lower intestine may be carried out by rectal suppositories (see above) or suitable enema formulations. Topical transdermal patches may also be used. For topical administration, the pharmaceutical composition may be formulated as a suitable ointment, lotion, or cream containing the active ingredient suspended or dissolved in one or more carriers.

[0350] In some embodiments, the pharmaceutical composition may also be formulated ophthalmologically as a granular suspension in isotonic, pH-adjusted sterile saline, or preferably as a solution in isotonic, pH-adjusted sterile saline, with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic use, the pharmaceutical composition may be formulated as an ointment such as petrolatum.

[0351] In some embodiments, the pharmaceutical composition may be administered by nasal aerosol or inhalation. Such compositions may be prepared according to techniques well known in the art of pharmaceutical formulations and may be prepared as a solution in physiological saline using benzyl alcohol or other suitable preservatives, absorption enhancers to increase bioavailability, fluorocarbons and / or other conventional solubilizers or dispersants.

[0352] In some embodiments, the pharmaceutical composition used for in vivo administration can be sterilized. This can be easily achieved, for example, by filtration through a sterile filtration membrane.

[0353] Pharmaceutical compositions within the scope of this disclosure include all compositions in which the solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III) is combined with one or more pharmaceutically acceptable carriers or diluents. In one embodiment, the solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III) is present in the composition in an amount effective to achieve the intended therapeutic outcome.

[0354] The pharmaceutical compositions of this disclosure can be administered to any patient who may be able to experience the beneficial effects of the compound of formula (I), the compound of formula (II), or the compound of formula (III) in solid form. While mammals, such as humans and companion animals, constitute the majority of such patients, this disclosure is not intended to be limited thereto. In one embodiment, the patient is human.

[0355] In another embodiment, the Disclosure relates to a kit comprising a solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III), packaged in a manner that facilitates its use in carrying out the method of the Disclosure. In one embodiment, the kit comprises a solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III) (or a combination thereof), packaged in a container such as a sealed bottle or container, with a label on the container or included in the kit that describes how to use the compound or composition for carrying out the method of the Disclosure. In one embodiment, the compound or composition is packaged in unit dosage form. The kit may further include a device suitable for administering the composition according to the desired route of administration. In some embodiments, the Disclosure provides a kit comprising a solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, and instructions for administering the compound or a pharmaceutically acceptable salt or solvate thereof to a cancer patient.

[0356] In some embodiments, the disclosure provides a pharmaceutical composition comprising a compound of formula (I), a compound of formula (II), or a compound of formula (III) in solid form, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or diluent, wherein the pharmaceutical composition is intended for use in methods for treating cancer.

[0357] IV. Treatment method The compounds of formula (I) disclosed herein, the solid forms of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), and the solid forms of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazolo-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), as well as mixtures thereof, can be used to inhibit the activity of the USP1 protein. For example, in some embodiments, a method for inhibiting the USP1 protein involves contacting the USP1 protein with the solid forms of the compounds of formula (I), formula (II), or formula (III), or combinations thereof. This contact can be carried out in vitro or in vivo.

[0358] In some embodiments, the solid form of the compound of formula (I), the compound of formula (II), or the compound of formula (III) can be used to treat "USP1 protein-mediated disorders." USP1 protein-mediated disorders are any pathological conditions in which the USP1 protein is known to be involved. In some embodiments, USP1 protein-mediated disorders are proliferative disorders such as cancer.

[0359] This specification provides various methods for treating diseases and disorders using the solid-state forms of compounds of formula (I), formula (II), or formula (III). Exemplary diseases and disorders that can be treated with solid-state forms include, but are not limited to, cancer.

[0360] In some embodiments, a method for treating cancer is provided using a solid form of the compound of formula (I), the compound of formula (II), or the compound of formula (III). Such a method involves administering a therapeutically effective amount of the compound of formula (I), the compound of formula (II), or the compound of formula (III) in solid form to a subject having cancer.

[0361] In some embodiments, the cancers to be treated in solid form disclosed herein are selected from the group consisting of hematological cancers, lymphomas, and DNA repair pathway deficiency cancers. In some embodiments, the cancers to be treated are cancers containing cancer cells with mutations in the gene encoding p53. In some embodiments, the cancers to be treated are cancers containing cancer cells with loss-of-function mutations in the gene encoding p53.

[0362] In some embodiments, the cancers to be treated in solid form disclosed herein are selected from the group consisting of non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer. In some embodiments, the cancer is ovarian cancer or breast cancer. In some embodiments, the cancer is ovarian cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the cancer is triple-negative breast cancer.

[0363] In some embodiments, the cancers to be treated in solid form disclosed herein are selected from the group consisting of bone cancers, including osteosarcoma and chondrosarcoma; brain cancers, including glioma, gliablastoma, astrocytoma, medulloblastoma, and meningioma; soft tissue cancers, including rhabdoid and sarcoma; kidney cancer; bladder cancer; skin cancers, including melanoma; and lung cancers, including non-small cell lung cancer.

[0364] In some embodiments, this disclosure provides a method for treating cancer, comprising administering one or more solid forms disclosed herein to a patient in need. In some embodiments, this disclosure provides a method for treating cancer, comprising administering one or more pharmaceutical compositions disclosed herein to a patient in need. In some embodiments, this disclosure provides a method for treating cancer, comprising administering one or more solid dosage forms disclosed herein to a patient in need.

[0365] In some embodiments, the Disclosure provides a method for treating cancer, comprising administering a solid form disclosed herein or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline form A, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, to a patient in need. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form A to a patient in need. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form F to a patient in need. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form 1 to a patient in need. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form 2 to a patient in need. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form 8 to a patient in need. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form 9 to a patient who requires it. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form A1 to a patient who requires it. In some embodiments, the Disclosure provides a method for treating cancer, comprising administering crystalline form B1 to a patient who requires it.

[0366] In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering a solid form disclosed herein or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline form A, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, to a patient in need. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form A to a patient in need. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form F to a patient in need. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form 1 to a patient in need. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form 2 to a patient in need. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form 8 to a patient in need. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form 9 to a patient who requires it. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form A1 to a patient who requires it. In some embodiments, the Disclosure provides a method for treating breast cancer, comprising administering crystalline form B1 to a patient who requires it.

[0367] In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering a solid form disclosed herein or a pharmaceutically acceptable salt thereof, selected from the group consisting of crystalline form A, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, to a patient in need. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form A to a patient in need. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form F to a patient in need. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form 1 to a patient in need. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form 2 to a patient in need. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form 8 to a patient in need. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form 9 to a patient who requires it. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form A1 to a patient who requires it. In some embodiments, the Disclosure provides a method for treating ovarian cancer, comprising administering crystalline form B1 to a patient who requires it.

[0368] The present invention provides various methods for treating cancer with a compound of formula (I), a compound of formula (II), or a compound of formula (III). In some embodiments, a therapeutically effective amount of a compound of formula (I), a compound of formula (II), or a compound of formula (III) is administered to a subject having cancer, where the cancer comprises cancer cells with elevated levels of RAD18. In some embodiments, the elevated level of RAD18 is an elevated level of RAD18 protein. In some embodiments, the elevated level of RAD18 is an elevated level of RAD18 mRNA. In some embodiments, the elevated level of RAD18 (e.g., RAD18 protein and / or RAD18 mRNA) is detected before administration (e.g., in a cancer sample taken from the subject). That is, in some embodiments, the cancer of the subject is tested for RAD18 protein or mRNA before initiating treatment with a USP1 inhibitor.

[0369] In some embodiments, a method for treating such cancer comprises (a) identifying whether the cancer of interest is a USP1 inhibitor-sensitive cancer, and (b) then administering a therapeutically effective amount of a compound of formula (I), a compound of formula (II), or a compound of formula (III) in solid form to the subject.

[0370] In some embodiments, such a method includes (a) detecting the level of RAD18 (e.g., RAD18 protein and / or RAD18 mRNA) in cancer cells (e.g., in a cancer sample taken from a subject), and (b) then administering a therapeutically effective amount of the compound of formula (I), the compound of formula (II), or the compound of formula (III) to a subject having cancer containing cells with elevated levels of RAD18.

[0371] In some embodiments, such a method involves administering a therapeutically effective amount of the compound of formula (I), the compound of formula (II), or the compound of formula (III) to a subject with triple-negative breast cancer.

[0372] In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer is homologous recombination-deficient cancer. In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer comprises cancer cells with mutations in the gene encoding p53. In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer comprises cancer cells with loss-of-function mutations in the gene encoding p53. In some embodiments, cancer without a homologous recombination pathway is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III).

[0373] In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer is a BRCA1-mutated cancer. In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer is a BRCA2-mutated cancer. In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer is a BRCA1-mutated cancer and a BRCA2-mutated cancer. In some embodiments, the cancer is neither a BRCA1-mutated cancer nor a BRCA2-mutated cancer. In some embodiments, the cancer is a BRCA1-deficient cancer. In some embodiments, the cancer is a BRCA2-deficient cancer. In some embodiments, the cancer is a BRCA1-deficient cancer and a BRCA2-mutated cancer.

[0374] In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer is PARP inhibitor-resistant cancer. In some embodiments, cancer is treated using a compound of formula (I), a compound of formula (II), or a compound of formula (III), where the cancer is PARP inhibitor-resistant BRCA1-deficient cancer.

[0375] In some embodiments, the cancer is a BRCA1 and / or BRCA2 mutant cancer, where the cancer includes cells with elevated levels of RAD18, for example, the elevated level of RAD18 is at least as high as the RAD18 protein and / or mRNA levels in ES2 cells, or higher than the RAD18 protein and / or mRNA levels in HEP3B217 cells. In some embodiments, the triple-negative breast cancer is a BRCA1 and / or BRCA2 mutant cancer.

[0376] In some cases, the cancer is a solid tumor. In some cases, the cancer is a blood / lymphoid cancer. In some cases, the cancer is a DNA repair pathway deficiency cancer. In some cases, the cancer is a homologous recombination deficiency cancer. In some cases, the cancer contains cancer cells with mutations in the gene encoding p53. In some cases, the cancer contains cancer cells with loss-of-function mutations in the gene encoding p53. In some cases, the cancer is selected from the group consisting of non-small cell lung cancer (NSCLC), osteosarcoma, ovarian cancer, and breast cancer (including triple-negative breast cancer). In some cases, the cancer is ovarian cancer or breast cancer (including triple-negative breast cancer). In some cases, the cancer is ovarian cancer. In some cases, the cancer is breast cancer (including triple-negative breast cancer).

[0377] In some embodiments, a compound of formula (I), a compound of formula (II), or a compound of formula (III) is used in combination with one or more additional therapeutic agents to treat cancer. It has been previously reported that the p53 status determines ionizing radiation-induced PARP inhibitor sensitization in several BRCA1 and HR-rich tumor types (Sizemore et al., Mol. Cancer Res. 16:1092-1102 (2018)). As shown below, p53-mutated cancers and BRCA-mutated cancers were increasedly sensitive to USP1 inhibitors. Therefore, in some embodiments, a compound of formula (I), a compound of formula (II), or a compound of formula (III) is used in combination with a PARP inhibitor to treat cancer.

[0378] In some embodiments, this disclosure provides the use of one or more of the solid forms disclosed herein for the manufacture of a drug for the treatment of cancer. In some embodiments, this disclosure provides the use of one or more of the pharmaceutical compositions disclosed herein for the manufacture of a drug for the treatment of cancer. In some embodiments, this disclosure provides the use of one or more of the solid dosage forms disclosed herein for the manufacture of a drug for the treatment of cancer.

[0379] In some embodiments, the Disclosure provides the use of one or more solid forms disclosed herein, selected from the group consisting of crystalline forms A, C, D, E, F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, or pharmaceutically acceptable salts thereof, for the manufacture of a drug for the treatment of cancer. In some embodiments, the Disclosure provides the use of crystalline form A for the manufacture of a drug for the treatment of cancer. In some embodiments, the Disclosure provides the use of crystalline form F for the manufacture of a drug for the treatment of cancer. In some embodiments, the Disclosure provides the use of crystalline form 1 for the manufacture of a drug for the treatment of cancer. In some embodiments, the Disclosure provides the use of crystalline form 2 for the manufacture of a drug for the treatment of cancer. In some embodiments, the Disclosure provides the use of crystalline form 8 for the manufacture of a drug for the treatment of cancer. In some embodiments, the Disclosure provides the use of crystalline form 9 for the manufacture of a drug for the treatment of cancer. In some embodiments, the Disclosure provides the use of crystalline form A1 for the manufacture of a drug for the treatment of cancer. In some embodiments, this disclosure provides the use of crystalline form B1 for the manufacture of pharmaceuticals for the treatment of cancer.

[0380] In some embodiments, the Disclosure provides the use of one or more solid forms disclosed herein, selected from the group consisting of crystalline forms A, C, D, E, F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, or pharmaceutically acceptable salts thereof, for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the Disclosure provides the use of crystalline form A for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the Disclosure provides the use of crystalline form F for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the Disclosure provides the use of crystalline form 1 for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the Disclosure provides the use of crystalline form 2 for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the Disclosure provides the use of crystalline form 8 for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the Disclosure provides the use of crystalline form 9 for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the Disclosure provides the use of crystalline form A1 for the manufacture of a drug for the treatment of breast cancer. In some embodiments, the present disclosure provides the use of crystalline form B1 for the manufacture of pharmaceuticals for the treatment of breast cancer.

[0381] In some embodiments, the Disclosure provides the use of one or more solid forms disclosed herein, selected from the group consisting of crystalline forms A, C, D, E, F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, or pharmaceutically acceptable salts thereof, for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the Disclosure provides the use of crystalline form A for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the Disclosure provides the use of crystalline form F for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the Disclosure provides the use of crystalline form 1 for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the Disclosure provides the use of crystalline form 2 for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the Disclosure provides the use of crystalline form 8 for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the Disclosure provides the use of crystalline form 9 for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the Disclosure provides the use of crystalline form A1 for the manufacture of a therapeutic drug for ovarian cancer. In some embodiments, the present disclosure provides the use of crystalline form B1 for the manufacture of therapeutic drugs for ovarian cancer.

[0382] In some embodiments, the disclosure provides a solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein the solid form is intended for use in methods of treating cancer.

[0383] In some embodiments, the Disclosure provides solid forms disclosed herein or pharmaceutically acceptable salts thereof, selected from the group consisting of crystalline forms A, C, D, E, F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, for use in methods of treating cancer. In some embodiments, the Disclosure provides crystalline form A for use in methods of treating cancer. In some embodiments, the Disclosure provides crystalline form F for use in methods of treating cancer. In some embodiments, the Disclosure provides crystalline form 1 for use in methods of treating cancer. In some embodiments, the Disclosure provides crystalline form 2 for use in methods of treating cancer. In some embodiments, the Disclosure provides crystalline form 8 for use in methods of treating cancer. In some embodiments, the Disclosure provides crystalline form 9 for use in methods of treating cancer. In some embodiments, the Disclosure provides crystalline form A1 for use in methods of treating cancer. In some embodiments, this disclosure provides a crystalline form B1 for use in methods for treating cancer.

[0384] In some embodiments, the Disclosure provides solid forms disclosed herein or pharmaceutically acceptable salts thereof, selected from the group consisting of crystalline forms A, C, D, E, F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, for use in methods of treating breast cancer. In some embodiments, the Disclosure provides crystalline form A for use in methods of treating breast cancer. In some embodiments, the Disclosure provides crystalline form F for use in methods of treating breast cancer. In some embodiments, the Disclosure provides crystalline form 1 for use in methods of treating breast cancer. In some embodiments, the Disclosure provides crystalline form 2 for use in methods of treating breast cancer. In some embodiments, the Disclosure provides crystalline form 8 for use in methods of treating breast cancer. In some embodiments, the Disclosure provides crystalline form 9 for use in methods of treating breast cancer. In some embodiments, the Disclosure provides crystalline form A1 for use in methods of treating breast cancer. In some embodiments, this disclosure provides a crystalline form B1 for use in methods for treating breast cancer.

[0385] In some embodiments, the Disclosure provides solid forms disclosed herein or pharmaceutically acceptable salts thereof, selected from the group consisting of crystalline forms A, C, D, E, F, crystalline form 1, crystalline form 2, crystalline form 3, crystalline form 4, crystalline form 5, crystalline form 6, crystalline form 7, crystalline form 8, crystalline form 9, crystalline form A1, crystalline form B1, and mixtures thereof, for use in methods of treating ovarian cancer. In some embodiments, the Disclosure provides crystalline form A for use in methods of treating ovarian cancer. In some embodiments, the Disclosure provides crystalline form F for use in methods of treating ovarian cancer. In some embodiments, the Disclosure provides crystalline form 1 for use in methods of treating ovarian cancer. In some embodiments, the Disclosure provides crystalline form 2 for use in methods of treating ovarian cancer. In some embodiments, the Disclosure provides crystalline form 8 for use in methods of treating ovarian cancer. In some embodiments, the Disclosure provides crystalline form 9 for use in methods of treating ovarian cancer. In some embodiments, the Disclosure provides crystalline form A1 for use in methods of treating ovarian cancer. In some embodiments, this disclosure provides a crystalline form B1 for use in methods for treating ovarian cancer.

[0386] V. Preparation method In one embodiment, the present disclosure relates to a method for preparing a solid form of a compound of formula (I), a compound of formula (II), or a compound of formula (III).

[0387] In some embodiments, the method is a) Adding a suitable amount of compound (I), compound (II), or compound (III) to a suitable solvent system to obtain a suspension, b) Stirring the suspension, c) Collecting the solid product from step b), and the following:

[0388] In some embodiments, a suitable pharmaceutically acceptable acid is added during step a).

[0389] In some embodiments, preferred solvent systems are selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropyl alcohol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyltetrahydrofuran, n-heptane, n-methylpyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof. In some embodiments, preferred solvent systems are selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.

[0390] In some embodiments, the method is a) Dissolving a suitable amount of compound (I), compound (II), or compound (III) in a suitable amount of a suitable solvent to prepare a solution, b) Add a suitable amount of a suitable poor solvent, c) Adding a seed crystal in solid form of the compound of formula (I), the compound of formula (II), or the compound of formula (III), d) Stirring the resulting suspension, e) Collecting the solid product generated in step d), and the following:

[0391] In some embodiments, the method further includes adding a suitable pharmaceutically acceptable acid during step a).

[0392] In some embodiments, the method further includes adding a suitable poor solvent after step c) and before step d).

[0393] In some embodiments, preferred and poor solvents are selected from the group consisting of acetonitrile, acetone, cyclohexane, dichloromethane, dimethylacetamide, dimethyl sulfoxide, ethanol, ethyl acetate, isopropyl alcohol, isopropyl acetate, methanol, methyl ethyl ketone, 4-methyl-2-pentanone, methyl tert-butyl ether, 2-methyltetrahydrofuran, n-heptane, n-methylpyrrolidone, tetrahydrofuran, toluene, water, and mixtures thereof. In some embodiments, preferred and poor solvents are selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof. In some embodiments, the preferred solvent is ethyl acetate. In some embodiments, the preferred poor solvent is n-heptane.

[0394] In some embodiments, the compound of formula (I), the compound of formula (II), and the compound of formula (III) are added to a suitable solvent system at a temperature of approximately room temperature to about 100°C, or approximately room temperature to about 75°C, or approximately room temperature to about 50°C, or approximately room temperature to about 40°C. In some embodiments, the compound of formula (I), the compound of formula (II), and the compound of formula (III) are added to a suitable solvent system at approximately room temperature.

[0395] In some embodiments, the present disclosure relates to a method for preparing crystalline form 2 of a gentisic acid cocrystal of a compound of formula (II), wherein the method is a) Adding a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid to a suitable solvent system at room temperature to obtain a suspension, b) Stirring the suspension from step a), c) Collecting the solid product from step b), and the following:

[0396] In some embodiments, preferred solvent systems are selected from the group consisting of ethyl acetate, n-heptane, and mixtures thereof.

[0397] In some embodiments, the present disclosure relates to a method for preparing crystalline form 2 of a gentisic acid cocrystal of a compound of formula (II), wherein the method is a) Dissolve a suitable amount of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and gentisic acid in a suitable amount of a suitable solvent at room temperature to prepare a solution, b) Add a suitable amount of a suitable poor solvent, c) Add a seed crystal of crystalline form 2 of the gentisic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), d) Stirring the resulting suspension, e) Collecting the solid product generated in step d), and the following:

[0398] In some embodiments, the method further includes adding a suitable poor solvent after step c) and before step d).

[0399] In some embodiments, a suitable solvent is ethyl acetate. In some embodiments, a suitable poor solvent is n-heptane.

[0400] In one embodiment, the present disclosure relates to crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0401] In another aspect, the present disclosure relates to the crystalline form C of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0402] In another aspect, the present disclosure relates to crystalline form D of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0403] In another aspect, the present disclosure relates to the crystalline form E of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0404] In another aspect, the present disclosure relates to the crystalline form F of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0405] In another aspect, the present disclosure relates to a crystalline form 1 of the hydrochloride salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0406] In another aspect, the present disclosure relates to crystalline form 2 of a gentisic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0407] In another aspect, the present disclosure relates to a crystalline form 8 of a benzoic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0408] In another aspect, the present disclosure relates to a crystalline form 9 of a salicylic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), prepared by any of the methods disclosed herein.

[0409] In another aspect, the present disclosure relates to crystalline form A1 of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), prepared by any of the methods disclosed herein.

[0410] In another aspect, the present disclosure relates to crystalline form B1 of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), prepared by any of the methods disclosed herein. [Examples]

[0411] [Table 21]

[0412] B. Experimental Method Equipment conditions X-ray powder diffraction (XRPD) patterns were measured using an X'Pert 3 X-ray powder diffractometer with Cu-kα radiation. Each sample was spread in the center of a zero-background silicon holder. The tube voltage and amperage were set to 45kV and 40mA, respectively. A 2-theta (2θ°) continuous scan was used at 46.7 seconds / step in the range of 3° to 40°2θ. The XRPD analysis conditions are shown in the table below. [Table 22]

[0413] To characterize the crystal morphology F, XRPD patterns were obtained using Cu-kα radiation in a PANanlytical & Xpert system. 3 Measurements were performed using an X-ray powder diffractometer. Each sample was spread in the center of a zero-background silicon holder. The tube voltage and amperage were set to 45kV and 40mA, respectively. A 2-theta (2θ°) continuous scan was used in the range of 2° to 50°2θ at 20.96 seconds / step. The XRPD analysis conditions are shown in the table below. [Table 23]

[0414] Thermogravimetric analysis (TGA) data were collected using TA Instruments' TA Q5000 and Discovery TGA 5500 TGA. The TGA analysis conditions are shown in the table below. [Table 24]

[0415] Differential scanning calorimetry (DSC) data was collected using a TA Q2000 DSC from TA Instruments. The DSC analysis conditions are shown in the table below. [Table 25]

[0416] DSC data was collected using a Perkin Elmer DSC 4000 to characterize crystal morphology F. The DSC analysis conditions are shown in the table below. [Table 26]

[0417] Polarized light (PLM) images were acquired using a ZEISS Scope A1 microscope.

[0418] Example 1: Preparation and characterization of crystal morphology A A. Preparation of the compound of formula (II) 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine was prepared according to the procedures disclosed in U.S. Provisional Applications No. 62 / 783,014, No. 62 / 799,423, and No. 62 / 868,616.

[0419] To an ice-cold solution of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine (1 equivalent) in dimethylformamide (5 mL), sodium hydride (60% dispersion in mineral oil) (1.2 equivalents) was gradually added, and the reaction mixture was stirred at the same temperature for 10 minutes. 2-iodopropane (1.20 equivalents) was added to the resulting reaction mixture, and stirring was continued at room temperature for 16 hours. The progress of the reaction was monitored by thin-layer chromatography (TLC) and liquid chromatography-mass spectrometry (LCMS). After completion, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 × 200 mL). The mixed organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude compound was purified by preparative high-performance liquid chromatography (HPLC) to obtain 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). Next, the purified compound was recrystallized with heptane and ethyl acetate using methods well known to those skilled in the art.

[0420] B. Characterization As described above, the 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) was subjected to XRPD, TGA, and DSC analysis using the conditions described above. The obtained XRPD patterns, DSC profiles, and TGA profiles are shown in Figures 1 and 2, respectively, and the XRPD peaks are shown in Table 1 above.

[0421] Based on the XRPD pattern shown in Figure 1, the XRPD peaks shown in Table 1, and the crystal structure and DSC and TGA profiles, the 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), obtained as described above, was determined to be a crystalline hydrate and named crystal morphology A.

[0422] C. Crystal structure determination Approximately 2.9 mg of crystalline form A was added to a 3 mL glass vial containing 0.5 mL of a DCM / n-heptane (1:4, v / v) solvent mixture. The mixture was then shaken in an ultrasonic cleaner to promote dissolution. The resulting suspension was filtered, and the resulting clear solution was transferred to a clean 4 mL shell vial (44.6 mm × 14.65 mm). The shell vial was sealed with a PE plug with a single pinhole. The shell vial was then placed in a fume hood and slowly evaporated at room temperature. After slow evaporation over one day, a cluster of massive crystals was observed.

[0423] Suitable single crystals with good diffraction quality were selected from the bulk crystal sample and covered with Paratone-N (an oil-based antifreeze). The crystals were placed in a Mylar loop with random orientation and immersed in a 120K nitrogen stream. Preliminary inspections and data acquisition were performed using a Rigaku XtaLAB Synergy R (CuKα radiation, λ=1.54184Å) diffractometer and analyzed using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software package. Lattice parameters and orientation matrices were extracted during data acquisition and refined using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software with 49,260 set reflection angles in the range of 3.563° < θ < 75.668° (T-vector Dirax algorithm). Data was collected at 120K within the range of minimum diffraction angle (θ) 3.591° and maximum diffraction angle (θ) 76.011°. The completeness of the final point cloud is 100%. The mean I / σ of the data is 69.7, and the highest resolution is rounded down to 0.79 Å.

[0424] Each frame was integrated using CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 57,364 reflections were collected, of which 5,292 were unique. Lorentz correction and polarization correction were applied to the data. Experimental absorption correction was performed using spherical harmonics incorporated into SCALE3 ABSPACK with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). The absorption coefficient μ of this material was 0.883 mm⁻¹ at this wavelength (λ=1.542 Å), and the minimum and maximum transmittances were 0.94414 and 1.0000, respectively. The coefficient of agreement for intensity-based averaging was 5.19%.

[0425] The structure was analyzed as the space group P21 / c using the ShelXT structural analysis program with Intrinsic Phasing, and F included in OLEX2 was analyzed. 2The model was refined using the ShelXL (Version 2018 / 3) refinement package with the full matrix least squares method. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were refined geometrically using a riding model.

[0426] XRPD pattern calculations for copper ("Cu") radiation were generated using the Mercury program and atomic coordinates, space group, and unit cell parameters of the single crystal structure. Crystal structure representations were created using Olex2 and Diamond. Atomic thermal displacement ellipsoid diagrams were created using ORTEP-III.

[0427] Suitable single crystals were separated from the massive crystal group and selected for single-crystal X-ray diffraction data collection. The single crystals were monoclinic with a P21 / c space group. Crystallographic data and refinement parameters are shown in Table 12. [Table 27]

[0428] As shown in Figure 20, the asymmetric unit of the single crystal structure consists of one free base compound molecule of formula (II) and non-integer water molecules, which suggests that crystal morphology A is a hydrate. The number of water molecules in the asymmetric unit was freely refined to 0.42 according to the thermal parameter.

[0429] Example 2: Preparation and Characterization of Crystal Form C A. Preparation A suitable amount of crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) was purged with nitrogen gas (N2) at 30°C for 20 minutes to form a new crystalline form.

[0430] B. Characterization XRPD analysis was performed on the new crystal morphology using the conditions described above. The obtained XRPD pattern is shown in Figure 3, and the XRPD peaks are shown in Table 2 above. Based on the XRPD pattern shown in Figure 3 and the XRPD peaks shown in Table 2, the new crystal morphology was determined to be anhydrous and named crystal morphology C.

[0431] Example 3: Preparation and Characterization of Crystal Form D A. Preparation A suitable amount of crystalline form C of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) was heated to 150°C under nitrogen to form a new crystalline form.

[0432] B. Characterization XRPD analysis was performed on the new crystal morphology using the conditions described above. The obtained XRPD pattern is shown in Figure 4, and the XRPD peaks are shown in Table 3 above. Based on the XRPD pattern shown in Figure 4 and the XRPD peaks shown in Table 3, the new crystal morphology was determined to be anhydrous and named crystal morphology D.

[0433] Example 4: Preparation and Characterization of Crystal Form E A. Preparation Approximately 20 mg of crystalline form A of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) was placed in a 3 mL vial. Next, the 3 mL vial was placed in a 20 mL vial containing approximately 4 mL of DCM. The 20 mL vial was sealed and stored at room temperature for 10 days. After 10 days, the resulting solution was evaporated at room temperature to obtain a solid substance.

[0434] B. Characterization The obtained solid material was subjected to XRPD, TGA, and DSC analysis using the conditions described above. The obtained XRPD patterns, DSC profiles, and TGA profiles are shown in Figures 5 and 6, respectively, and the XRPD peaks are shown in Table 4 above.

[0435] Based on the XRPD pattern shown in Figure 5, the XRPD peaks shown in Table 4, and the DSC and TGA profiles, the obtained solid material was determined to be a crystalline DCM solvate and named crystalline form E.

[0436] Example 5: Preparation and Characterization of Crystal Form 1 A. Preparation Approximately 20 mg of crystalline form A was mixed with hydrochloric acid in a 1:1 ratio in an HPLC vial. Next, 0.5 mL of siRNA / n-heptane (1:1, v / v) was added to form a suspension, which was stirred at approximately 1000 rpm at room temperature for about 3 days. The resulting solid was separated by centrifugation and dried under reduced pressure at room temperature.

[0437] B. Characterization XRPD, TGA, and DSC analyses were performed on the obtained solid material using the conditions described above. The obtained XRPD patterns, DSC profiles, and TGA profiles are shown in Figures 7 and 8, respectively, and the XRPD peaks are shown in Table 6 above.

[0438] Based on the XRPD pattern shown in Figure 7, the XRPD peaks shown in Table 6, and the DSC and TGA profiles, the obtained solid material was determined to be the crystalline hydrate of the HCl salt of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), and was named crystal form 1.

[0439] Example 6: Preparation and Characterization of Crystal Form 2 A. Preparation Method A: Approximately 40 mg of crystalline form A and 11.6 mg of gentisic acid were mixed with 0.5 mL of dimethyl / n-heptane to obtain a suspension. The suspension was stirred at room temperature for 2 days, and the solid material was separated by vacuum filtration and dried at room temperature under reduced pressure. The obtained solid material can be used as a "seed" to prepare crystalline form 1 on a larger scale.

[0440] Method B: Approximately 500 mg of crystalline form A and 11.6 mg of gentisic acid were mixed with 7 mL of ¼ to obtain a solution. Next, 5.0 mL of n-heptane was added dropwise along with 10.2 mg of gentisic acid cocrystal "seed" prepared by Method A, and finally 8.0 mL of n-heptane was added to obtain a suspension. The suspension was stirred at room temperature for 2 days. The resulting solid material was separated by vacuum filtration and dried under reduced pressure at room temperature.

[0441] B. Characterization The obtained solid material was subjected to XRPD, TGA, and DSC analysis using the conditions described above. The obtained XRPD patterns, DSC profiles, and TGA profiles are shown in Figures 9-10, respectively, and the XRPD peaks are shown in Table 7 above.

[0442] Based on the XRPD pattern shown in Figure 9, the XRPD peaks shown in Table 7, and the crystal structure and DSC and TGA profiles, the obtained solid material was determined to be a crystalline anhydride of gentisinic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II), and was named crystal form 2.

[0443] C. Crystal structure determination Approximately 3.0 mg of crystalline form 2 was added to a 3 mL glass vial containing 0.5 mL of a THF / n-heptane (2:5, v / v) solvent mixture. The mixture was then shaken in an ultrasonic cleaner to promote dissolution. The resulting suspension was filtered, and the resulting clear solution was transferred to a clean 4 mL shell vial (44.6 mm × 14.65 mm). The shell vial was sealed with a PE plug with a single pinhole. The shell vial was then placed in a fume hood and slowly evaporated at room temperature. After slow evaporation over 6 days, a cluster of massive crystals was observed.

[0444] Suitable single crystals with good diffraction quality were selected from the bulk crystal sample and covered with Paratone-N (an oil-based antifreeze). The crystals were placed in a Mylar loop with random orientation and immersed in a 120K nitrogen stream. Preliminary inspections and data acquisition were performed using a Rigaku XtaLAB Synergy R (CuKα radiation, λ=1.54184Å) diffractometer and analyzed using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software package. Lattice parameters and orientation matrices were extracted during data acquisition and refined using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software with 50,053 set reflection angles in the range of 3.539° < θ < 75.936° (T-vector Dirax algorithm). Data was collected at 120K within the range of minimum diffraction angle (θ) 3.765° and maximum diffraction angle (θ) 76.018°. The completeness of the final point cloud is 100%. The mean I / σ of the data is 75.8, and the highest resolution is rounded down to 0.79 Å.

[0445] Each frame was integrated using CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 58,850 reflections were collected, of which 6,566 were unique. Lorentz correction and polarization correction were applied to the data. Experimental absorption correction was performed using spherical harmonics incorporated into SCALE3 ABSPACK with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). The absorption coefficient μ of this material is 0.927 mm at this wavelength (λ=1.542 Å). -1 The minimum and maximum transmittances were 0.75213 and 1.0000, respectively. The agreement factor for averaging based on intensity was 3.94%.

[0446] The structure was analyzed as the space group P21 / c using the ShelXT structural analysis program with Intrinsic Phasing, and F included in OLEX2 was analyzed. 2 The matrix was refined using the ShelXL (Version 2018 / 3) refinement package with a full matrix least squares method. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms (H2) bonded to oxygen atoms (O2) were freely identified and refined based on Fourier maps. Other hydrogen atoms were geometrically calculated and refined using a riding model.

[0447] XRPD pattern calculations for copper ("Cu") radiation were generated using the Mercury program, as well as atomic coordinates, space group, and unit cell parameters of the single crystal structure. Crystal structure representations were created using Olex2 and Diamond. Thermal ellipsoid diagrams were created using ORTEP-III.

[0448] Suitable single crystals were separated from the massive crystal group and selected for single-crystal X-ray diffraction data acquisition. The crystal system of the single crystals was determined to be monoclinic, and the space group was determined to be P21 / c. The crystallographic data and refinement parameters are shown in Table 13. [Table 28]

[0449] As shown in Figure 21, the asymmetric unit of the single crystal structure consists of one neutral compound molecule of formula (II) and one neutral gentisic acid molecule, indicating that crystal form 2 is actually a cocrystal of the starting compound and gentisic acid.

[0450] Example 7: Preparation and Characterization of Crystal Form 3 A. Preparation Approximately 20 mg of crystalline form A was mixed with hydrochloric acid in a 1:2 molar ratio (form A / acid) in an HPLC vial. Next, 0.5 mL of MTBE was added to form a suspension, which was then magnetically stirred (approximately 1000 rpm) at room temperature for about 3 days. The resulting solid was dried under reduced pressure at room temperature.

[0451] B. Characterization XRPD analysis was performed on the obtained solid material using the conditions described above. The obtained XRPD pattern is shown in Figure 15. The new crystal morphology was named crystal morphology 3.

[0452] Example 8: Preparation and Characterization of Crystal Form 4 A. Preparation Approximately 20 mg of crystalline form A was mixed with hydrobromic acid in a 1:1 molar ratio (form A / acid) in an HPLC vial. Next, 0.5 mL of MTBE was added to form a suspension, which was then magnetically stirred (approximately 1000 rpm) at room temperature for about 3 days. The resulting solid was dried under reduced pressure at room temperature.

[0453] B. Characterization XRPD analysis was performed on the obtained solid material using the conditions described above. The obtained XRPD pattern is shown in Figure 16. The new crystal morphology was named crystal morphology 4.

[0454] Example 9: Preparation and Characterization of Crystal Form 5 A. Preparation Approximately 20 mg of crystalline form A was mixed with hydrobromic acid in a 1:1 molar ratio (form A / acid) in an HPLC vial. Next, 0.5 mL of toluene / n-heptane (1:1, v / v) was added to form a suspension, which was then magnetically stirred (approximately 1000 rpm) at room temperature for about 3 days. The resulting solid was dried under reduced pressure at room temperature.

[0455] B. Characterization XRPD analysis was performed on the obtained solid material using the conditions described above. The obtained XRPD pattern is shown in Figure 17. The new crystal morphology was named crystal morphology 5.

[0456] Example 10: Preparation and Characterization of Crystal Form 6 A. Preparation Approximately 20 mg of crystalline form A was mixed with ethane disulfonic acid in a 1:1 molar ratio (form A / acid) in an HPLC vial. Next, 0.5 mL of acetone / n-heptane (1:4, v / v) was added to form a suspension, which was then magnetically stirred (approximately 1000 rpm) at room temperature for about 3 days. The resulting solid was dried under reduced pressure at room temperature.

[0457] B. Characterization XRPD analysis was performed on the obtained solid material using the conditions described above. The obtained XRPD pattern is shown in Figure 18. The new crystal morphology was named crystal morphology 6.

[0458] Example 11: Preparation and Characterization of Crystal Form 7 A. Preparation Approximately 20 mg of crystalline form A was mixed with methanesulfonic acid in a 1:1 molar ratio (form A / acid) in an HPLC vial. Next, 0.5 mL of acetone / n-heptane (1:4, v / v) was added to form a suspension, which was then magnetically stirred (approximately 1000 rpm) at room temperature for about 3 days. The resulting solid was dried under reduced pressure at room temperature.

[0459] B. Characterization XRPD analysis was performed on the obtained solid material using the conditions described above. The obtained XRPD pattern is shown in Figure 19. The new crystal morphology was named crystal morphology 7.

[0460] Example 12: Preparation and Characterization of Crystal Form A1 A. Preparation A purified 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) was prepared according to the procedures disclosed in U.S. Provisional Applications Nos. 62 / 783,014, 62 / 799,423, and 62 / 868,616. The purified compound was then recrystallized in hexane and isopropanol using methods well known to those skilled in the art.

[0461] B. Characterization As described above, the 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) obtained was subjected to XRPD, TGA, and DSC analysis using the conditions described above. The obtained XRPD patterns, DSC profiles, and TGA profiles are shown in Figures 11-12, respectively, and the XRPD peaks are shown in Table 10 above.

[0462] Based on the XRPD pattern shown in Figure 11, the XRPD peaks shown in Table 7, and the crystal structure and DSC and TGA profiles, the 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazole-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), obtained as described above, was determined to be a crystalline anhydride and named crystal form A1.

[0463] C. Crystal structure determination Approximately 4.8 mg of crystalline form A1 was added to a 3 mL glass vial containing 0.5 mL of an EtOH / n-heptane (1:3, v / v) solvent mixture. Dissolution was promoted by shaking in an ultrasonic cleaner, and the suspension was filtered. The resulting clear solution was transferred to a clean 4 mL shell vial (44.6 mm × 14.65 mm). The shell vial was sealed with a PE plug with a single pinhole. Next, the shell vial was placed in a fume hood and slowly evaporated at room temperature. After slow evaporation over 5 days, a cluster of thin, rod-shaped crystals was observed.

[0464] Suitable single crystals with good diffraction quality were selected from thin rod-shaped crystal samples and coated with Paratone-N (an oil-based antifreeze). The crystals were placed in Mylar loops with random orientations and immersed in a 120K nitrogen stream. Preliminary inspections and data acquisition were performed using a Rigaku XtaLAB Synergy R (CuKα radiation, λ=1.54184Å) diffractometer and analyzed using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software package. Lattice parameters and orientation matrices were extracted during data acquisition and refined using the CrysAlisPro (V1.171.40.19a, Rigaku, 2018) software with 24,455 set reflection angles in the range of 3.516° < θ < 75.351° (T-vector Dirax algorithm). Data was collected at 120K within the range of minimum diffraction angle (θ) 3.541° and maximum diffraction angle (θ) 75.982°. The completeness of the final point cloud is 100%. The mean I / σ of the data is 71.4, and the highest resolution is rounded down to 0.79 Å.

[0465] Each frame was integrated using CrysAlisPro (V1.171.40.19a, Rigaku, 2018). A total of 52,006 reflections were collected, of which 4,790 were unique. Lorentz correction and polarization correction were applied to the data. Experimental absorption correction was performed using spherical harmonics incorporated into SCALE3 ABSPACK with CrysAlisPro (V1.171.40.19a, Rigaku, 2018). The absorption coefficient μ of this material is 0.932 mm at this wavelength (λ=1.542 Å). -1 The minimum and maximum transmittances were 0.72018 and 1.0000, respectively. When the equivalent reflection intensities were averaged, the coefficient of agreement for intensity-based averaging was 3.24%.

[0466] The structure was analyzed as the space group P21 / c using the ShelXT structural analysis program with Intrinsic Phasing, and F included in OLEX2 was analyzed. 2 The model was refined using the ShelXL (Version 2018 / 3) refinement package with the full matrix least squares method. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were refined geometrically using a riding model.

[0467] XRPD pattern calculations for Cu radiation were generated using the Mercury program, as well as atomic coordinates, space group, and unit cell parameters of the single crystal structure. Crystal structure representations were created using Olex2 and Diamond. Atomic thermal displacement ellipsoid diagrams were created using ORTEP-III.

[0468] Suitable single crystals were separated from a group of thin, rod-shaped crystals and selected for single-crystal X-ray diffraction data collection. The crystal system of the single crystals was determined to be monoclinic, and the space group was P21 / c. Crystallographic data and refinement parameters are shown in Table 14. [Table 29]

[0469] As shown in Figure 22, the asymmetric unit of the single crystal structure consists of only one compound molecule of formula (III), which suggests that crystal morphology A1 is an anhydrous form.

[0470] Example 13: Preparation and Characterization of Crystal Form B1 A. Preparation Approximately 20 mg of crystalline form A1 was suspended in 0.5 mL of dimethyl / n-heptane (1:2, v / v) in an HPLC vial and magnetically stirred (approximately 1000 rpm) at room temperature for about 3 days. The resulting solid material was dried under reduced pressure at room temperature.

[0471] B. Characterization The obtained solid material was subjected to XRPD, TGA, and DSC analysis using the conditions described above. The obtained XRPD patterns, DSC profiles, and TGA profiles are shown in Figures 13-14, respectively, and the XRPD peaks are shown in Table 11 above.

[0472] Based on the XRPD pattern shown in Figure 13, the XRPD peaks shown in Table 8, and the DSC and TGA profiles, the obtained solid material was determined to be a crystalline anhydride and named crystal morphology B1.

[0473] Example 14: Pharmacokinetic studies in mice Crystal form A of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine disclosed herein, 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole- Mouse pharmacokinetic (PK) studies were conducted using crystalline form 2 of the gentisic acid cocrystal of 2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine and crystalline form 8 of the benzoic acid cocrystal of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine disclosed herein.

[0474] The PK study was a single-dose oral exposure study conducted in female NOD / SCID mice (approximately 6-8 weeks old, 20-30g at the time of the study) using a compound dose of 300 mg / kg and a dosage volume of 10 mL / kg. The mice were fasted overnight before administration. After administration, the animals were allowed free access to food and water.

[0475] Blood samples were continuously collected from the dorsal metatarsal vein before administration and at 0.25, 0.5, 1, 2, 4, 8, 24, 48 (crystal morphology 2 only) and 72 hours (crystal morphology 2 only) after PO administration. At each time point, approximately 0.03 mL of blood was collected and centrifuged at 4000 G for 5 minutes at 4°C to obtain plasma. The plasma samples were then frozen and stored at -75 ± 15°C before LC-MS / MS analysis.

[0476] Next, the concentrations of each compound in the plasma sample were analyzed using LC-MS / MS. WinNonlin (Phoenix™, version 6.1) or other similar software was used for PK calculations. The following PK parameters, C max , T max , T 1 / 2 AUC inf , and AUClast The PK was calculated as much as possible from time-series data of plasma concentrations. PK data was expressed using descriptive statistics such as the mean and standard deviation.

[0477] The results for crystal morphology A are shown in Table 15 and Figure 23 below. [Table 30]

[0478] The results for crystal morphology 2 are shown in Table 16 and Figure 24 below. [Table 31]

[0479] Example 15: Preparation and Characterization of Crystal Form F A. Preparation A mixture of formula (II) (1 g) was heated under reflux in 50% acetone / water (10 vol) and the temperature was maintained for at least 30 minutes. The resulting clear solution was then cooled to room temperature and stirred overnight. The resulting slurry was filtered and dried to obtain morphology F (800 mg) as a white solid.

[0480] B. Characterization XRPD and DSC analysis were performed on the obtained white solid material using the conditions described above. The obtained XRPD pattern and DSC profile are shown in Figures 25 and 26, respectively, and the XRPD peaks are shown in Table 5.

[0481] Based on the XRPD pattern shown in Figure 25, the XRPD peaks shown in Table 5, and the DSC profile shown in Figure 26, the obtained solid material was determined to be a crystalline anhydride and named crystal morphology F.

[0482] Example 16: Additional cocrystal screening Further cocrystal screening was performed to identify additional solid forms of equation (II).

[0483] A.Equipment Differential scanning calorimetry (DSC) was performed using a TA Instruments Q2000 instrument (closed aluminum sample pan with a pinhole in the lid, heating rate 20 K / min). The melting point is understood as the peak value.

[0484] Optical microscopy was performed using a Leitz Orthoplan polarizing microscope, part number 130880, with a magnification of 10 × 10 generally applied.

[0485] X-ray powder diffraction (XRPD) was performed using a Stoe Stadi P diffractometer equipped with a Mythen 1K detector operating with Cu-Kα radiation. Measurements with this instrument were performed in transmission mode with a tube voltage of 40 kV and tube power of 40 mA. Testing with Cu-Kα1 radiation is possible using a curved Ge monochromator. The following parameters were set: step size of 0.02°²θ, step time of 12 seconds, scanning range of 1.5 to 50.5°²θ, and detector step of 1°²θ (detector in step scan mode). In typical sample preparation, approximately 10 mg of sample was placed between two acetate foils and placed inside the Stoe transmission sample holder. The sample was rotated during measurement. All sample preparation and measurements were performed in an ambient air environment.

[0486] TG-FTIR measurements were performed using a Netzsch Thermo-Microblanace TG209 coupled to a Bruker FTIR Spectrometer Vector 22 (sample pan with pinholes, N2 environment, heating rate 10°C / min up to 300 or 350°C).

[0487] B. Starting materials The starting material was in the form of the free base shown in formula (II).

[0488] Salt and cocrystal screening Cocrystal screening experiments for Equation II were conducted using adipic acid, benzoic acid, ethyl maltol, gallic acid (3,4,5-trihydroxybenzoic acid), ethyl gallate, 4-hydroxybenzoic acid, methyl 4-hydroxybenzoate, nicotinic acid, nicotinamide, L-proline, saccharin, salicylic acid, D-sorbitol, and succinic acid. The experimental parameters and results of the cocrystal screening experiments are shown in Table 17.

[0489] [Table 32-1] [Table 32-2] [Table 32-3] [Table 32-4] [Table 32-5]

[0490] Example 17: Characterization of Crystal Form 8 A. Characteristic evaluation The benzoic acid cocrystals from Experiment 5 in Table 17 were analyzed via XRPD. DSC and TG-FTIR analyses were performed using the conditions described above. The obtained XRPD patterns, DSC profiles, and TG-FTIR profiles are shown in Figures 29-31, respectively, and the XRPD peaks are shown in Table 8.

[0491] Based on the XRPD pattern shown in Figure 29, as well as the DSC and TGA profiles, the obtained solid material was determined to be a benzoic acid cocrystal and named crystal morphology 8.

[0492] B. Crystal structure determination Approximately 82.4 mg of the benzoic acid cocrystal starting material of formula (II) was added to a 3 mL glass vial containing 2.0 mL of an EtOH / n-heptane (1:6, v / v) solvent mixture. The suspension was magnetically stirred (1,000 rpm) at room temperature for 5 days and filtered through a 0.45 μm PTFE membrane. Next, 0.5 mL of the clear filtrate was transferred to a clean 4 mL shell vial (44.6 mm × 14.65 mm). The shell vial was sealed with a PE plug with one pinhole and placed in a fume hood, where it was slowly evaporated at room temperature. After slow evaporation over 14 days, a cluster of massive crystals was observed.

[0493] A suitable single crystal with good diffraction quality was selected from a bulk crystal sample and covered with Paratone-N (an oil-based antifreeze). The crystals were placed in a Mylar loop with random orientation and immersed in a 120K nitrogen stream. Preliminary testing and data acquisition were performed using Rigaku XtaLAB Synergy R(CuK α The analysis was performed using an X-ray diffractometer (λ=1.54184 Å) and the CrysAlisPro (V1.171.40.67a, Rigaku, 2019) software package.

[0494] During data acquisition, lattice parameters and orientation matrices were extracted and refined using CrysAlisPro (V1.171.40.67a, Rigaku, 2019) software (T-vector Dirax algorithm) with 37,110 set reflection angles in the range of 3.716° < θ < 75.227°. Data were collected at 120K with a minimum diffraction angle (θ) of 3.734° and a maximum diffraction angle (θ) of 76.055°. Completeness is 100%. The mean I / σ of the data is 64.1, and the highest resolution is rounded down to 0.79 Å.

[0495] Each frame was integrated using CrysAlisPro (V1.171.40.67a, Rigaku, 2019). A total of 66,366 reflections were collected, of which 6,371 were unique. Lorentz correction and polarization correction were applied to the data. Experimental absorption correction was performed using spherical harmonics incorporated into SCALE3 ABSPACK with CrysAlisPro (V1.171.40.67a, Rigaku, 2019). The absorption coefficient μ of this material is 0.882 mm at this wavelength (λ=1.542 Å). -1 The minimum and maximum transmittances were 0.7464 and 1.0000, respectively. Equivalent reflection intensities were averaged. The coefficient of agreement for intensity-based averaging was 3.65%.

[0496] The structure was analyzed as a space group P21 / n using the ShelXT (Sheldrick, GMActa Cryst. 2015, A71, 3-8) structural analysis program with intrinsic phasing, and F included in OLEX2 (Dolomanov, OV, Bourhis, LJ, Gildea, RJ, Howard, JAK & Puschmann, HJAppl.Cryst. 2009, 42, 339-341) 2 The matrix was refined using the ShelXL (Version 2018 / 3) refinement package (Sheldrick, GMActa Cryst.2015, C71, 3-8) with the full matrix least squares method. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms (H2) bonded to oxygen atoms (O2) were freely identified and refined based on Fourier maps. Other hydrogen atoms were geometrically calculated and refined using a riding model.

[0497] XRPD pattern calculations for Cu radiation were generated using the Mercury program (Macrae, CF, Edgington, PR, McCabe, P., Pidcock, E., Shields, GP, Taylor, R., Towler, M. & van de Streek, JJAppl.Cryst.2006, 39, 453-457), as well as atomic coordinates, space group, and unit cell parameters of the single crystal structure.

[0498] Crystal structure representations were created using Olex2 and Diamond (Brandenburg, K. DIAMOND, 1999, Crystal Impact GbR, Bonn, Germany). Thermal ellipsoid diagrams were created using ORTEP-III (LJFarrugia.J.Appl.Cryst.2012,45,849-854).

[0499] Suitable single crystals were separated from the massive crystal group and selected for single-crystal X-ray diffraction data collection. The crystal system of the single crystals was determined to be monoclinic, and the space group was determined to be P21 / n. The crystallographic data and refinement parameters are shown in Table 18. [Table 33]

[0500] As shown in Figure 32, the asymmetric unit of the single crystal structure consists of one neutral compound molecule of formula (II) and one neutral benzoic acid molecule, indicating that the crystal is a benzoic acid cocrystal of formula (II).

[0501] Example 18: Characterization of Crystal Form 9 A. Characteristic evaluation The salicylic acid cocrystals from Experiment 29 in Table 17 were subjected to XRPD and the above conditions. 1 Analysis was performed via 1H NMR analysis. The obtained XRPD and 1 The 1H NMR patterns are shown in Figures 33-34, respectively.

[0502] The XRPD pattern shown in Figure 33, and 1 Based on the 1H NMR profile (Figure 34), the obtained solid material was determined to be a salicylic acid cocrystal and named crystal morphology 9.

[0503] A. Crystal structure determination Approximately 3.2 mg of salicylic acid cocrystal of formula (II) was added to a 3 mL glass vial containing an additional 0.5 mL of acetone / n-heptane (1:8, v / v) solvent mixture. Sonar treatment was applied to promote the dissolution of the solid sample, and the suspension was then filtered through a filter (0.45 μm PTFR membrane). The clear filtrate was then transferred to a clean 4 mL shell vial (44.6 mm × 14.65 mm). The shell vial was sealed with a PE plug with a single pinhole. The shell vial was placed in a fume hood and allowed to evaporate slowly at room temperature. After slow evaporation over two days, a cluster of rod-shaped crystals was observed.

[0504] Suitable single crystals with good diffraction quality were selected from rod-shaped crystal samples and covered with Paratone-N (an oil-based antifreeze). The crystals were placed in a Mylar loop with random orientation and immersed in a nitrogen stream at 184 K. Preliminary testing and data acquisition were performed using a Bruker D8 Venture (METALJET GaX source, PHOTON II) diffractometer, and the data was analyzed using the APEX3 software package.

[0505] During data acquisition, lattice parameters and orientation matrices were extracted and refined using SAINT (version: 8.37A) software with 9,918 set reflection angles in the range of 3.252° < θ < 54.786°. Data were collected at 184K with a minimum diffraction angle (θ) of 3.506° and a maximum diffraction angle (θ) of 55.323°. Completeness is 99.84%. The mean I / σ of the data is 13.0, and the highest resolution is rounded down to 0.82 Å.

[0506] Each frame was integrated using SAINT (version: 8.37A). A total of 38,333 reflections were collected, of which 6,058 were unique. Lorentz correction and polarization correction were applied to the data. Absorption correction was performed using SADABS (version: 2016 / 2) with a multiscan method. The absorption coefficient μ of this material was 0.579 mm⁻¹ at this wavelength (λ=1.34139 Å), and the minimum and maximum transmittances were 0.5107 and 0.7508, respectively. The coefficient of agreement for intensity-based averaging was 12.23%.

[0507] The structure is created using ShelXT with Intrinsic Phasing. 1 The structural analysis program was used to analyze the space group P21 / c, and F included in OLEX2 was analyzed. 2 ShelXL using the full matrix least squares method for the following 2 (Version 2018 / 3) Improved with the refinement package. All non-hydrogen atoms were anisotropically refined. Hydrogen atoms (H2) bonded to oxygen atoms (O2) were freely identified and refined based on Fourier maps. Other hydrogen atoms were geometrically calculated and refined using a riding model.

[0508] The XRPD pattern of Cu radiation was calculated using the Mercury program, as well as atomic coordinates, space group, and unit cell parameters of the single crystal structure. The crystal structure representation was created using Olex2 and Diamond.

[0509] Suitable single crystals were separated from the massive crystal group and selected for single-crystal X-ray diffraction data acquisition. The crystal system of the single crystals was determined to be monoclinic, and the space group was determined to be P21 / c. Crystallographic data and refinement parameters are shown in Table 19. [Table 34]

[0510] As shown in Figure 35, the asymmetric unit of the single crystal structure consists of one neutral compound molecule of formula (II) and a neutral salicylic acid molecule, indicating that the crystal is a salicylic acid cocrystal of formula (II).

[0511] Example 19: Pharmacokinetic studies in mice Mouse pharmacokinetic (PK) studies were conducted using the crystalline form 8 of 6-(4-cyclopropyl-6-methoxypyrimidine-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazole-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine disclosed herein.

[0512] The PK study was a single-dose oral exposure study conducted in female NOD / SCID mice (approximately 6-8 weeks old, 20-30g at the time of the study) using a compound dose of 300 mg / kg and a dosage volume of 10 mL / kg. The mice were fasted overnight before administration. After administration, the animals were allowed free access to food and water.

[0513] Blood samples were continuously collected from the dorsal metatarsal vein before administration and at 0.25, 0.5, 1, 2, 4, 8, and 24 hours after PO administration. Approximately 0.03 mL of blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4°C to obtain plasma. The plasma samples were then frozen and stored at -75 ± 15°C before LC-MS / MS analysis.

[0514] Next, the concentrations of compounds in the plasma samples were analyzed using LC-MS / MS. WinNonlin (Phoenix™, version 6.1) or other similar software was used for PK calculations. The following PK parameters, C max , T max , T 1 / 2 AUC inf , and AUC last The PK was calculated as much as possible from time-series data of plasma concentrations. PK data was expressed using descriptive statistics such as the mean and standard deviation.

[0515] The results for crystal morphology 8 are shown in Table 20 and Figure 36 below. [Table 35]

[0516] Example 20: Distribution of crystal morphology 2 in mouse brain and plasma Female NOD SCID mice, 6–8 weeks old and weighing between 18–22 g, were purchased from Beijing Anikeeper Biotech Co., Ltd. The animals were acclimatized to the environment for at least 7 days prior to the start of the study. The mice were administered crystalline form 2 at dose levels of 100 mg / kg or 300 mg / kg via oral force-feeding for 28 days. Three mice were euthanized by CO2 24 hours after 27 doses of the compound. Three mice were euthanized by CO2 4 hours after 28 doses of the compound. Whole brains were collected at each time point. In addition, approximately 0.03 mL of blood was collected at each time point and centrifuged at 4000 G for 5 minutes at 4°C to obtain plasma. The samples were then frozen at -75 ± 15°C before LC-MS / MS analysis. The concentrations of the compound in brain homogenate (ng / g) and plasma (ng / ml) were then analyzed using LC-MS / MS. PK data was represented using descriptive statistics such as the mean and standard deviation.

[0517] As shown in Table 20 and Figure 37, measurable drug levels were observed in brain tissue. No drug accumulation in the brain was observed after repeated administration. [Table 36]

[0518] Example 21. Distribution of crystal morphology 2 in rat brain and plasma. Male and female Sprague Dawley rats were purchased from Beijing Anikeeper Biotech Co., Ltd. The animals were acclimated to the environment before the start of the study. The rats were given a single dose of 100 mg / kg of crystalline form 2 via oral force-feeding. The rats were fasted overnight before administration. Two hours after administration, the animals were given food, and throughout the study, they had free access to water. At each time point, a sample of approximately 0.2 mL of blood was taken via the jugular vein and centrifuged at 4000 G for 5 minutes at 4°C to obtain plasma. The samples were then frozen and stored at -75 ± 15°C before LC-MS / MS analysis. The whole brain was collected after hemoperfusion, snap-frozen on dry ice, and then stored at -75 ± 15°C. Before LC-MS / MS analysis, the whole brain was weighed and homogenized with water until the ratio of tissue weight (g) to water volume (ml) was 1:3 before analysis. The actual concentration was obtained by multiplying the measured value by the dilution factor. PK data was represented using descriptive statistics such as the mean and standard deviation.

[0519] As shown in Table 21 and Figure 38, measurable drug levels were observed in brain tissue. Similar excretion profiles were also observed between plasma and brain tissue, suggesting a rapid equilibrium between systemic circulation and brain tissue. [Table 37]

[0520] Although the present invention has been fully described, it will be understood by those skilled in the art that the same can be implemented within a broad range of equivalent conditions, formulations, and other parameters without affecting the scope of the invention or any of its embodiments.

[0521] Other embodiments of the present invention will be apparent to those skilled in the art in consideration of the specification and practice of the present invention disclosed herein. This specification and examples should be considered merely illustrative, and the scope and spirit of the present invention are intended to be indicated by the following claims.

[0522] All patents and documents cited herein are incorporated herein by reference in their entirety.

Claims

1. Formula (I): 【Chemistry 1】 (Wherein, R is C 1-3 is alkyl, and X 1 and X 2 are independently selected from the group consisting of N and C. A solid form of a compound of the formula:

2. Formula (II): 【Chemistry 2】 2. The solid form of claim 1, which is a solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, or a pharma- ceutically acceptable salt thereof.

3. 3. The solid form of claim 2, wherein the solid form is a pharma- ceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and (i) a second pharma- ceutically acceptable compound or (ii) a pharma- ceutically acceptable acid.

4. The solid form of claim 2, wherein the solid form is a pharma- ceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine represented by formula (II) and a pharma- ceutically acceptable acid, wherein the pharma- ceutically acceptable acid is gentisic acid.

5. 5. The solid form of claim 4, wherein the gentisic acid co-crystal is crystalline form 2 characterized by an XRPD pattern with peaks at 16.6±0.2°, 18.7±0.2°, and 22.5±0.2° 2θ.

6. (i) Figure 9 below: [Figure 9] or (ii) an endothermic peak at about 186.0° C. as measured by DSC; or (iii) Figure 10 below: [Figure 10] or (iv) a loss of about 3.17% by weight between room temperature and about 170° C. as measured by TGA; or (v) Figure 10 below: [Figure 10] or (vi) The following a) to c): a) Figure 9 below: [Figure 9] The XRPD pattern shown in b) Figure 10 below: [Figure 10] The DSC profile shown in c) Figure 10 below: [Figure 10] The TGA profile shown in At least two of 5. The solid form of claim 4, characterized by:

7. 7. A mixture comprising the solid form of claim 5 or 6 and a second solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II).

8. a) crystalline form A, characterized by an XRPD pattern having peaks at 14.3±0.2°, 21.5±0.2°, and 21.8±0.2° 2θ; b) crystalline form C, characterized by an XRPD pattern having peaks at 14.2±0.2°, 17.0±0.2°, and 19.1±0.2° 2θ; c) crystalline form D, characterized by an XRPD pattern having peaks at 13.9±0.2°, 15.2±0.2°, and 19.3±0.2° 2θ; d) crystalline form E, characterized by an XRPD pattern having peaks at 10.6±0.2°, 18.7±0.2°, and 20.9±0.2° 2θ; and e) crystalline form F, characterized by an XRPD pattern having peaks at 10.7±0.2°, 14.3±0.2°, and 21.8±0.2° 2θ; and combinations thereof, A solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) according to claim 2, selected from the group consisting of:

9. The solid form is crystalline form A, and the solid form has one of the following: a) Figure 1 below: [Figure 1] The XRPD pattern shown in b) an endothermic peak at about 165° C. as measured by DSC; c) Figure 2 below: [Figure 2] The DSC profile shown in d) a loss of about 0.93% by weight between room temperature and about 150° C. as measured by TGA; and e) Figure 2 below: [Figure 2] The TGA profile shown in 9. The solid form of claim 8, wherein the solid form is characterized by at least one of:

10. 10. A mixture comprising the solid form of claim 9 and a second solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II). (i) The solid form is crystalline form C, and the solid form has the structure shown in Figure 3 below: [Figure 3] or (ii) the solid form is crystalline form D, and the solid form has the structure shown in Figure 4 below: [Figure 4] or (iii) The solid form is crystalline form E, and the solid form has any of the following: a) Figure 5 below: [Figure 5] The XRPD pattern shown in b) an endothermic peak at about 107° C. as measured by DSC; c) Figure 6 below: [Figure 6] The DSC profile shown in d) a loss of about 13.5% by weight between room temperature and about 200° C. as measured by TGA; and e) Figure 6 below: [Figure 6] The TGA profile shown in or (iv) The solid form is crystalline form F, and the solid form has one of the following: a) Figure 25 below: [Figure 25] The XRPD pattern shown in b) an endothermic peak at about 157° C. as measured by DSC; and c) Figure 26 below: [Figure 26] The DSC profile shown in may be characterized by one of:

9. The solid form of claim 8.

12. 12. A mixture comprising the solid form of claim 11 and a second solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II).

13. the solid form being a pharma- ceutically acceptable salt of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II); The pharma- ceutically acceptable salt may be formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a pharma-ceutically acceptable acid.

3. The solid form of claim 2.

14. the pharma- ceutically acceptable salt is the hydrochloride salt; The solid form comprises any one of the following: a) Figure 7 below: [Figure 7] The XRPD pattern shown in b) an endothermic peak at about 142.1° C. as measured by DSC; c) Figure 8 below: [Figure 8] The DSC profile shown in d) a loss of about 4.04% by weight between about 30° C. and about 100° C. as measured by TGA; and e) Figure 8 below: [Figure 8] The TGA profile shown in and 14. The solid form of claim 13.

15. 15. The solid form of claim 14, wherein the hydrochloride salt is crystalline Form 1 characterized by an XRPD pattern with peaks at 12.5±0.2°, 22.4±0.2°, and 23.9±0.2°2θ.

16. The method of claim 1, wherein the solid form is a pharma- ceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II) and a pharma- ceutically acceptable acid, wherein the pharma- ceutically acceptable acid is benzoic acid; The solid form comprises one of the following: a) Figure 29 below: [Figure 29] The XRPD pattern shown in b) Figure 30 below: [Figure 30] The DSC profile shown in c) Figure 31 below: [Figure 31] The TG-FTIR profile shown in and 3. The solid form of claim 2.

17. 17. The solid form of claim 16, wherein the benzoic acid co-crystal is a crystalline form 8 characterized by an XRPD pattern with peaks at 12.1±0.2°, 14.2±0.2°, and 16.5±0.2°2θ.

18. The method of claim 17, wherein the solid form is a pharma- ceutically acceptable co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine represented by formula (II) and a pharma- ceutically acceptable acid, wherein the pharma- ceutically acceptable acid is salicylic acid; The solid form comprises the following: a) Figure 33 below: [Figure 33] The XRPD pattern shown in b) Figure 34 below: [Figure 34] The 1 H NMR profile shown in and 3. The solid form of claim 2.

19. 20. The solid form of claim 18, wherein the salicylic acid co-crystal is crystalline form 9 characterized by an XRPD pattern with peaks at 11.0±0.2°, 16.5±0.2°, 17.3±0.2°, and 25.3±0.2°2θ.

20. 20. A mixture comprising the solid form of any one of claims 14 to 19 and a second solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (II).

21. Formula (III): 【Chemistry 3】 2. The solid form of claim 1, which is a solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine, or a pharma- ceutically acceptable salt thereof.

22. a) crystalline form A1, characterized by an XRPD pattern having peaks at 16.1±0.2°, 16.7±0.2°, and 24.8±0.2° 2θ; b) crystalline form B1, characterized by an XRPD pattern having peaks at 12.9±0.2°, 14.5±0.2°, and 22.6±0.2° 2θ; and combinations thereof, A solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine represented by formula (III) according to claim 21, selected from the group consisting of:

23. said solid form being crystalline form A1; The solid form comprises any one of the following: a) Figure 11 below: [Figure 11] The XRPD pattern shown in b) an endothermic peak at about 150.5° C. as measured by DSC; c) Figure 12 below: [Figure 12] The DSC profile shown in d) a loss of about 0.95% by weight between room temperature and about 120° C. as measured by TGA; and e) Figure 12 below: [Figure 12] The TGA profile shown in and 23. The solid form of claim 22.

24. said solid form being crystalline form B1; The solid form comprises any one of the following: a) Figure 13 below; [Figure 13] The XRPD pattern shown in b) an endothermic peak at about 161.2° C. as measured by DSC; c) Figure 14 below: [Figure 14] The DSC profile shown in d) a loss of about 1.58% by weight between room temperature and about 120° C. as measured by TGA; and e) Figure 14 below: [Figure 14] The TGA profile shown in and 23. The solid form of claim 22.

25. 25. A mixture comprising the solid form of claim 23 or 24 and a second solid form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III).

26. the solid form is a pharma- ceutically acceptable salt or co-crystal of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III), The pharma- ceutically acceptable salt or co-crystal may be formed between 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of formula (III) and a pharma- ceutically acceptable acid.

22. The solid form of claim 21.

27. (i) The crystalline form A has a unit cell classified as monoclinic; or (ii) said crystalline form A has a unit cell with an a value of about 12.054 Å, a b value of about 8.775 Å, and a c value of about 24.837 Å; or (iii) said crystalline form A has a unit cell with a volume of about 2603.68 Å 3 ; 10. The solid form of claim 9.

28. (i) The crystalline form 2 has a unit cell classified as monoclinic; or (ii) said crystalline Form 2 has a unit cell with an a value of about 11.113 Å, a b value of about 12.356 Å, and a c value of about 24.048 Å; or (iii) said crystalline form 2 has a unit cell with a volume of about 3223.93 Å 3 ; 6. The solid form of claim 5.

29. (i) The crystalline form A1 has a unit cell classified as monoclinic; or (ii) the crystalline form A1 has a unit cell with an a value of about 12.545 Å, a b value of about 8.640 Å, and a c value of about 21.660 Å; or (iii) said crystalline form A1 has a unit cell with a volume of about 2336.13 Å 3 ; 24. The solid form of claim 23.

30. 30. The solid form or mixture of any one of claims 1 to 29, wherein said solid form is substantially free of other polymorphic forms.

31. (i) The pharma- ceutical acceptable cocrystal is a hydrate, anhydrate, or solvate thereof, and the solvate may be a dichloromethane solvate; or (ii) the solid form is a crystalline form; or (iii) the pharma- ceutically acceptable salt is a hydrate, anhydrate, or solvate thereof, the solvate optionally being a dichloromethane solvate; or (iv) the pharma- ceutically acceptable salt is a hydrochloride salt; or (v) the solid form is an amorphous form; or (vi) the pharma- ceutically acceptable acid is 1-hydroxy-2-naphthoic acid, 4-aminosalicylic acid, ascorbic acid, adipic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, trans-cinnamic acid, citric acid, ethanedisulfonic acid, fumaric acid, galactaric acid, gentisic acid, gluconic acid, D-glucuronic acid, glutamic acid, glutaric acid, glycolic acid, hexanoic acid, hippuric acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, L-malic acid, malonic acid, R-mandelic acid, methanesulfonic acid, or is selected from the group consisting of carboxylic acid, ... (vii) the pharma-ceutically acceptable acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, ethanedisulfonic acid, methanesulfonic acid, gentisic acid, benzoic acid, salicylic acid, and gallic acid; or (viii) the pharma- ceutically acceptable acid is gentisic acid; A solid form or mixture according to any one of claims 1 to 30.

32. A pharmaceutical composition comprising one or more of the solid forms or mixtures according to any one of claims 1 to 31 and one or more pharma- ceutically acceptable carriers or diluents.

33. A solid formulation comprising one or more of the solid forms or mixtures according to any one of claims 1 to 31.

34. Use of one or more of the solid forms or mixtures according to any one of claims 1 to 31, the pharmaceutical composition according to claim 32, or the solid formulation according to claim 33, for the manufacture of a medicament for the treatment of cancer.

35. 33. The pharmaceutical composition of claim 32 for the treatment of cancer.